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ABSTRACT 
The Role of CCL5 (RANTES) in the Immune Response Against Mycobacterium 
tuberculosis in the Guinea Pig.  (December 2004) 
Troy Arthur Skwor, B.S., University of Wisconsin – Madison  
Chair of Advisory Committee:  Dr. David N. McMurray 
 
 
 
Tuberculosis is the second leading cause of morbidity and mortality worldwide 
due to an infectious disease.  Development of a new tuberculosis (TB) vaccine would be 
facilitated by a better understanding of the mechanisms of protection induced by the 
current TB vaccine, Mycobacterium bovis BCG.  Recombinant guinea pig (rgp)CCL5 
and anti-rgpCCL5 were developed and characterized.  The biological activity of 
rgpCCL5 was determined in a chemotaxis assay using T lymphocytes and pleural 
exudate cells.  The specificity of rabbit anti-rgpCCL5 polyclonal antibody was 
confirmed by Western blot.  RgpCCL5 was used to stimulate alveolar and peritoneal 
macrophages in vitro. and cytokine/chemokine gene expression was evaluated using 
real-time PCR.  RgpCCL5 stimulated TNFα, IL-1β, CCL2, and CXCL8 mRNA 
expression and TNFα protein production (as assessed in the L929 cell bioassay) in 
macrophages.  The effect of BCG-vaccination on CCL5 expression and production in 
leukocytes infected with M. tuberculosis was examined in vitro and in vivo.  Polyclonal 
anti-rgpCCL5 was used to develop an ELISA assay to quantify gpCCL5 protein levels, 
and real-time PCR was used to detect CCL5 mRNA.  Leukocytes isolated from BCG-
vaccinated guinea pigs and infected in vitro with virulent M. tuberculosis demonstrated 
 iv
significantly elevated gpCCL5 mRNA and protein compared to cells from naive 
animals.  The response of gpCCL5 to M. tuberculosis in vivo was studied in tuberculous 
pleural effusions, where peak levels of CCL5 mRNA and protein were reached at day 4 
post-induction.  Disease severity, cellular differentiation, histology, and 
cytokine/chemokine mRNA levels in pleural cells and granulomas were analyzed on day 
4 in guinea pigs induced with tuberculous pleurisy and treated with either rgpCCL5 or 
anti-rgpCCL5 by direct intra-pleural injection.  In these studies, neutralizing CCL5 
resulted in reduced macrophage accumulation, diminished levels of IFNγ, TNFα, and 
CCL5 mRNA in pleural effusion cells, and reduced spontaneous lymphocyte 
proliferation.  Together these studies suggest an important role for gpCCL5 in activating 
leukocytes during M. tuberculosis infection.
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CHAPTER I   
 
INTRODUCTION 
 
TUBERCULOSIS EPIDEMIOLOGY 
Tuberculosis has plagued mankind for thousands of years.  Archeological 
evidence has displayed uncontested evidence of tuberculosis in Dynasty mummies as far 
back as 1000 B.C.  Today the causative agent, Mycobacterium tuberculosis, is still 
estimated to infect one-third of the world’s population and claims more than 2 million 
lives a year (56).  The majority of these cases occur in sub-Saharan Africa and Southeast 
Asia, however, due to the increased international travel this disease presents as a global 
threat.  Until the mid–1980s, tuberculosis appeared to be declining in many developed 
countries (31).  It is believed that the resurgence of tuberculosis was related to the 
development of the HIV pandemic.  Numerous areas with high prevalence of 
tuberculosis correlated with endemic areas of HIV, with Africa reporting up to one-third 
of TB cases being HIV-positive (56).   
 
PATHOGENESIS OF M. tuberculosis 
The pathogenesis of tuberculosis begins when a droplet nucleus (< 5µm in size) 
containing M. tuberculosis is inhaled by the host and proceeds down the airway until 
reaching the distal end of the respiratory tree, where the organisms enter the alveolar 
space.  In the alveolus, resident macrophages phagocytose ‘foreign invaders’ and what  
 
____________ 
This dissertation follows the style and format of Infection and Immunity. 
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occurs next determines the outcome of M. tuberculosis infection.  In the presence of an 
activated macrophage, the microbe is destroyed by reactive oxygen and nitrogen 
intermediates (ROIs and RNIs) (1, 42, 104).  If the alveolar macrophage is not activated, 
the microbe will remain in the lag phase for a few days and then proceed to undergo 
numerous rounds of replication (18-24 h per replication cycle) within the macrophage 
resulting in host cell death and the release of a plethora of organisms into the 
surrounding environment.  Products of these infected macrophages will attract numerous 
blood leukocytes to the site of infection, and the extracellular bacteria can then be 
internalized by incoming blood monocytes (21), neighboring alveolar macrophages (72), 
alveolar epithelial cells (20, 21, 71), neutrophils (97), and possibly M cells lining the 
bronchi (194).  The blood monocytes which ingest M. tuberculosis can mature into 
macrophages, but are unable to kill the microbe.  As a result, the organisms continue to 
replicate in these inflammatory cells, eventually destroying the cells resulting in the 
release of more bacteria into the environment.  This process is repeated continually until 
~ 2-3 weeks into infection when bacteria and/or their antigens are taken to draining 
lymph nodes via dendritic cells and presented to T cells.  Upon development of T cell 
immunity, antigen-specific T lymphocytes enter into inflamed foci, proliferate, and 
release interferon-γ (IFNγ), which synergistically works with tumor necrosis factor-α 
(TNFα) to activate surrounding macrophages enabling them to produce anti-
mycobacterial compounds (45, 62) .  These events result in the formation of a primary 
lesion (granuloma) and halt the logarithmic growth of the mycobacteria.  However, 
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mycobacteria escape from the primary lesion and get into the blood or lymph, thus 
disseminating to neighboring lymph nodes and/or other organs (spleen, liver, etc.), as 
well as reseeding the apical regions of the lung.  In healthy, HIV-negative individuals, 
around 90% of tuberculosis infections end here and do not progress to active disease.     
 
MACROPHAGE VERSUS M. tuberculosis  
Most likely the first encounter of mycobacteria with the host is the engulfment of 
the bacilli by alveolar macrophages.  It has been previously shown that M. tuberculosis 
binds to complement receptors (CR1, 3, and 4) (178, 179), Fc receptors (58), mannose 
receptors (155, 179), toll-like receptors (TLR2 and 4) (114, 131, 160, 202), scavenger 
receptors (216), fibronectin (151), and surfactant protein A (72, 124, 150).  These 
receptors act in an independent or concerted manner facilitating the uptake of M. 
tuberculosis.  It has been demonstrated that the method of internalization can affect the 
outcome of M. tuberculosis viability within the macrophage (199).  Once the tubercle 
bacillus is within the macrophage and residing in a phagosome, the fate of the pathogen 
lies with its ability to prevent fusion with the lysosome.  This organelle contains 
numerous degradative hydrolytic enzymes, as well as a lethal intravesicular acidic pH (~ 
4.5 – 5.0), that aid in the destruction of M. tuberculosis (15).  Previous studies have 
shown that viable, virulent M. tuberculosis can prevent phagosome-lysosome fusion and 
replicate within the phagosome (126), as well as preventing the development of a 
proton-ATPase on the vacuolar membrane.  However, attenuated M. tuberculosis 
H37Ra, M. bovis Bacille Calmette Guerin (BCG), and heat-killed H37Ra or H37Rv all 
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fail to inhibit lysosomal fusion resulting in destruction by ROI, RNI, and acidic 
environments.            
 
HOST RESPONSE TO M. tuberculosis 
Once M. tuberculosis is internalized by the alveolar macrophage, one of the host 
responses is to inform the neighboring cells of its presence.  This is accomplished by 
releasing an arsenal of molecules (i.e. cytokines and chemokines) to activate neighboring 
leukocytes, attract new inflammatory cells to the focus of infection, and regulate the host 
immune response.  The first cytokines released are a group of pro-inflammatory 
cytokines, which include TNFα, interleukin-1β (IL-1β), and IL-6.  TNFα is released 
from macrophages/monocytes (106), dendritic cells (74), and neutrophils (119) in 
response to either direct binding of the bacteria to the leukocyte or via secretory proteins 
from M. tuberculosis, including Ag85 (117), heat-shock protein 70 (207), and culture 
filtrate protein (CFP-10) (196).  The release of TNFα results in leukocyte activation via 
autocrine and paracrine pathways.  Previous studies have shown that humans and mice 
deficient in TNFα production have abnormal granuloma formation, succumb to 
tuberculosis infection more readily, and have elevated risk of tuberculosis reactivation 
(32, 63, 136).  IL-1β deficiencies display similar defects in infection control 
mechanisms.  In murine studies, it has been shown that the lack of IL-1 or absence of IL-
1 receptor results in granuloma abnormalities, and enhanced mycobacterial outgrowth 
(89).  In contrast, the impact of the other pro-inflammatory cytokine, IL-6, has been 
controversial.  This cytokine plays a regulatory role by reducing the production TNFα 
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and IL-1β (177).  In the absence of IL-6, mice expressed less IFNγ and more IL-4 
resulting in more rapid mortality from tuberculosis.  Interestingly, absence of IL-6 had 
no significant effect on bacterial burdens in the lung, liver, or spleen when mice were 
infected with BCG (102). 
 After the first 2-3 weeks of infection, memory T lymphocytes begin to appear at 
the foci of infection.  At this stage, it is essential for the host phagocytes to release 
cytokines favoring the differentiation of CD4+ T helper cells into Th1 effector cells.  
The production of IL-12, IL-18, and IL-23 are pivotal in this step.  These cytokines 
induce naive and memory T lymphocytes to release IFNγ (39, 96, 144, 200) which 
activates neighboring macrophages.  This is a crucial step in the cross-talk between 
macrophages and T lymphocytes, which work together to develop a protective, well-
localized granuloma (152).  The interaction of IFNγ with macrophages results in 
elevated levels of anti-mycobacterial molecules, including ROI and RNIs (50, 51, 152).  
Inside the granulomas, IFNγ also causes monocytes/macrophages to fuse, resulting in the 
formation of epithelioid and multi-nucleated giant cells around the nucleus of the 
granuloma (26).  These cells contain enhanced anti-mycobacterial components and are 
beneficial to the host defenses due to the heighten ability to secrete cytokines, ROIs, and 
RNIs.   
 As the infection progresses, it is beneficial for M. tuberculosis to attempt to 
induce the secretion of anti-inflammatory cytokines to suppress the anti-mycobacterial 
response.  This category of cytokines, including IL-4, IL-10, and transforming growth 
factor-β (TGFβ), can down-regulate TNFα, IFNγ, and IL-12 levels thus rendering the 
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host more susceptible to mycobacterial infection.  The interaction of lipoarabinomannans 
(LAM), which are cell wall components of mycobacteria, with human macrophages 
resulted in the production of the anti-inflammatory cytokine, TGFβ (41).  Other studies 
have demonstrated that the presence of TGFβ during M. tuberculosis infections can 
result in abrogated T cell blastogenesis (76) and increased bacterial replication within 
human monocytes (77).  Although IL-4 and IL-10 are Th2 cytokines with the potential to 
diminish IFNγ, TNFα, and IL-12, their impact on disease pathogenesis has been 
controversial (61, 199).       
  
CHEMOKINES AND M. tuberculosis  
In addition to the release of cytokines in response to M. tuberculosis proteins, an 
arsenal of chemokines are released by host cells following direct contact with M. 
tuberculosis or its products.  Chemokines are a group of small molecular weight (8-12 
kDa) proteins known for their chemotactic properties, and more recently associated with 
an array of diverse biological activities.  They are categorized into 4 groups based on the 
position of the first two cysteine residues.  The majority of inflammatory chemokines are 
in the α- (one amino acid separating the first two cysteine residues –CXC) or β- 
(adjacent cysteine residues –CC) chemokine families.  Human tuberculosis patients have 
heightened levels of chemokines CXCL8 (IL-8), CCL5, and CCL2 (MCP-1) in 
bronchoalveolar lavage fluid during acute and convalescent stages with more 
pronounced levels appearing during the acute phase (101).  Other studies described 
similar findings in the bronchoalveolar lavage fluid and serum, including CCL4 (MIP-
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1β) and IFN-inducible protein 10 (IP-10) (90, 167).   The first cells likely to interact 
with M. tuberculosis are alveolar macrophages and epithelial cells (20, 71).  Previous 
studies have shown human alveolar macrophages release CCL2, CCL3 (MIP-1α), 
CCL4, CCL5, IP-10, and CXCL8 (167, 174) when infected with M. tuberculosis.  The 
component of M. tuberculosis responsible for chemokine secretion in macrophages has 
been further elucidated in other studies.  Lipoarabinomannan (LAM) has been shown to 
induce CXCL8, CCL2, and CCL4 in monocytes/macrophages (90, 118).  In macaque 
peripheral blood mononuclear cells (PBMCs), M. tuberculosis heat shock protein 70 
(hsp70) induced CCL3 and CCL5 production (207).  Soluble tuberculosis factor was also 
shown to stimulate human alveolar macrophages to release CCL5 (88).  M. tuberculosis 
infection of the human alveolar epithelial cell line A549 resulted in CCL2, CXCL8, and 
CCL5 secretion (111, 173, 210).  Thus, the infection of these cell types results in a 
concerted release of chemokines, which could result in a chemotactic stimulus for 
leukocytes leading to the development of an anti-mycobacterial environment.  Some 
studies have characterized the variation of chemokine expression in mycobacterial (type-
1) versus schistosomal (type-2) antigen-elicited pulmonary granulomas in mice.  These 
studies demonstrated an enhanced mRNA expression and production of 6 chemokines, 
including IP-10, CCL3, CCL4, and CCL5 in type 1 granulomas compared to type 2 (35, 
158), suggesting the importance of chemokines populations during protective 
mycobacterial granuloma formation.     
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ROLE OF CCL5 DURING A M. tuberculosis INFECTION  
The availability of chemokine knock-out mice and neutralizing antibodies have 
facilitated the study of the role of chemokines during tuberculosis pathogenesis and their 
contribution to host protection.  Chensue et al. have shown that type 1 granulomas (PPD 
induced) in IFNγ -/- mice revert to a type 2 phenotype with diminished levels of CCL5 
production (34).  Neutralization of CCL5 with anti-CCL5 antibody resulted in 
diminished type 1 (PPD) granulomas while enhancing type 2 (Schistosoma mansoni egg) 
granulomas (35).  Treatment of mice the rhCCL5 resulted in significantly enhanced 
IFNγ, IL-2, IL-5, and IL-13 protein in PPD stimulated cells harvested from the 
mediastinal lymph nodes of PPD-immunized animals (35). 
Saukkonen et al. demonstrated increased viability of M. tuberculosis in human 
alveolar macrophages co-cultured with anti-CCL5 (174).  Whether this anti-
mycobacterial environment is the result of CCL5 directly or indirectly is an area of 
interest.  Locati et al. performed an elaborate study on the ability of rhCCL5 to activate 
human nonadherent blood monocytes.  They showed an up-regulation in mRNA 
expression levels of 114 genes out of 5600 human genes tested.  These genes were 
involved in many diverse physiological activities, including cytokine production, 
membrane receptors, regulators of tissue invasion, enzymes, signal transducers, nuclear 
proteins, and cytoskeleton-related proteins (113).  It is apparent that many of the genes 
grouped into tissue invasion, cytoskeleton-related proteins, and membrane receptors 
(including CD44, which has been associated with M. tuberculosis uptake (108)) are 
associated with chemotactic function.  However, many of these genes are associated 
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with cytokines and signal transducers that might be capable of further activating 
monocytes/macrophages and neighboring leukocytes.  Other studies have demonstrated 
the activating properties of CCL5 on T lymphocytes resulting in enhanced IL-2 and 
IFNγ production, as well as increased proliferative and cytotoxic activity (11, 14, 121, 
193).  The elevated levels of IFNγ can further activate macrophages resulting in the 
production of anti-mycobacterial compounds (50, 51).  Together these results suggest a 
possible role for CCL5 in eliciting mechanisms crucial for the development of a 
protective anti-mycobacterial environment. 
 
REGULATION OF CCL5 
Bi-directional communication occurs between CCL5 and cytokines.  It has been 
previously demonstrated that TNFα and IFNγ can act synergistically to enhance the 
production of CCL5 protein in endothelial and epithelial cells (29, 122, 189).  Casola et 
al. used a human alveolar epithelial cell line to demonstrate that TNFα induced CCL5 
mRNA promptly, and IFNγ enhanced the transcriptional level and stabilized the CCL5 
mRNA transcripts (29).  Of the studies to date, regulation of CCL5 expression in T 
lymphocytes is perhaps the best understood.  The transcription of CCL5 varies 
considerably from other chemokines in that is enhanced days after T cell activation, 
making it a ‘late’ transcript (187).  The upstream CCL5 promoter in T lymphocytes is 
composed of numerous sequences for DNA-binding proteins, including RANTES factor 
of late activated T lymphocytes-1 (RFLAT), interferon regulatory factor 3 (IRF-3), 
nuclear factor of IL-6 (NF-IL-6), NF-κB, rel p50/p50, and rel p50/p65 (140, 141, 187).  
 10
CCL5 has also been shown to be induced by type 1 IFNs via IFN-stimulated response 
element (ISRE) – like mechanisms (40).   The Th1 cytokine, IL-12, also can induce 
CCL5 secretion in CD4+ and CD8+ T cell clones (116).  Together these data suggest 
that cross-talk between cytokines and chemokines is necessary to orchestrate a protective 
immune response against M. tuberculosis.   
In these studies we attempted to further elucidate the contributions of gpCCL5 to 
the anti-mycobacterial immune response.
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CHAPTER II 
 
RECOMBINANT GUINEA PIG CCL5 (RANTES) DIFFERENTIALLY 
MODULATES CYTOKINE PRODUCTION IN ALVEOLAR AND 
PERITONEAL MACROPHAGES* 
 
 
INTRODUCTION  
During an infection, the leukocytes which are recruited to and reside in the 
tissues are constantly in contact with chemokines.  As these cells leave the circulation 
and enter the site of infection, they encounter increasing chemokine concentrations.  
This plays a role in attracting the cells to the infectious focus, but recent studies suggest 
that chemokines have effects on leukocyte functions which go beyond chemotaxis.  
CCL5, CCL3 (MIP-1α), and CCL4 (MIP-1β) have all been shown to activate 
macrophages (10, 27, 54, 203) and T lymphocytes (10, 11, 14, 120, 121, 193).  The 
differentiation of helper T lymphocytes into polarized Th1 and Th2 cytokine-producing 
subpopulations has been shown to be regulated by numerous chemokines, including 
CCL5 (54).  This chemokine is chemotactic for eosinophils (4), basophils (22), dendritic 
cells (43), macrophages/monocytes (27, 175), and T lymphocytes (175), including those 
of the Th1 phenotype (94).  
       The diverse physiological roles of CCL5 might be due to the large family of  
 
receptors through which it can signal.  Many of these receptor interactions are  
___________ 
*Reprinted with permission from “Recombinant guinea pig CCL5 (RANTES) 
differentially modulates cytokine production in alveolar and peritoneal macrophages” by 
Skwor, T. A., H. Cho, C. Cassidy, T. Yoshimura, and D. N. McMurray, 2004, Journal of 
Leukocyte Biology vol 76. 
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Determined by the concentration of CCL5 present.  CCL5 has been shown to interact 
with the G coupled protein receptors CCR1, 3, 4 and 5 at low concentrations (12), while 
at higher concentrations it appears to bind to glycosoaminoglycans (GAG) (80) and 
CD44 (165).  These various receptor interactions may allow CCL5 to trigger diverse 
cellular responses.   
      Lipopolysaccharide (LPS) induces a pronounced inflammatory response, which 
can eventually lead to septic shock syndrome (49).  Previous studies have demonstrated 
that LPS upregulates numerous cytokines and chemokines in naive macrophages (28, 46, 
99, 115, 118).  These molecules proceed to activate neighboring cells, resulting in a 
cascade of events leading to the recruitment of leukocytes to the site of infection.  
Chemokines are the primary inducers of leukocyte accumulation.  It is likely that 
leukocytes leaving the circulation to enter an inflammatory tissue focus would encounter 
host chemokines before interacting with products of an invading pathogen. 
      Previously, we have demonstrated that guinea pig CXCL8 (IL-8), CCL2 (MCP-
1), and CCL5 mRNA expression and/or secretion were enhanced in macrophages 
cultured with LPS or Mycobacterium tuberculosis (85, 118).  In the present studies, the 
ability of CCL5 to induce TNFα, IL-1β, CCL2, and CXCL8 expression in alveolar and 
peritoneal macrophages was evaluated.  In addition, we examined the effect of 
pretreatment with CCL5 on the ability of macrophages to respond to subsequent 
stimulation with LPS.           
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MATERIALS AND METHODS 
Production and purification of recombinant guinea pig (rgp) CCL5.  The 
sequence encoding the mature form of the protein, described by Campbell, et al. (27), 
was subcloned into the Novagen (Milwaukee, WI) pET30-Xa/LIC vector using the 
cDNA clone for gpCCL5, according to the protocol from Novagen.  The vector was 
transformed into E. coli BL21 (DE3) (Novagen) cells, which were grown in 1L of Luria-
Bertani broth (Becton Dickinson, Sparks, Maryland) with 50ug/ml kanamycin at 37°C.  
The production of rgpCCL5 was performed using a slightly modified protocol from 
Laurence, et al.  (107).  Briefly, the cells were induced with 0.1mM isopropyl-beta-D-
thiogalactopyranoside (IPTG) for 4 hours.  The cells were centrifuged and the pellet was 
resuspended in 500mM NaCl, 20 mM Tris, 1 mM ethylenediaminetetraacetic acid 
(EDTA), 5 mM benzamidine, and 5 mM β-mercaptoethanol at pH 7.4.  The suspension 
was exposed to two rounds of lysis in a French Press at 18,000-20,000 psi, and 
centrifuged at 18,500 × g for 60 minutes.  The pellet was then resuspended in denaturing 
buffer (5M guanidine hydrochloride, 50mM Tris, 50mM NaCl, 3mM EDTA, pH 7.4, 
and 5mM β-mercaptoethanol) and left for 2 h at room temperature.  Centrifugation of the 
denatured protein was performed at 18,500 × g for 60 min.  The supernatant was added 
to dilution buffer (50mM Tris, 50mM NaCl, pH 7.4, and 5mM β-mercaptoethanol) in a 
drop wise manner and allowed to sit for 4 h to refold the protein.  The solution was 
centrifuged for 30 min at 13,000 × g and purified by C4 reverse phase chromatography, 
using a Vydac column (Hesperia, CA).  The purified fractions were then lyophilized and 
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resuspended in 20mM Tris, 2mM CaCl, pH 7.4, and 100mM NaCl until an A280nm=0.3.  
Factor Xa (Novagen) was used for proteolysis at 2U/ml and incubated at room 
temperature for 24 h, followed by re-purification over a C4 column using reverse phase 
chromatography.  The samples were tested for purity by SDS-PAGE analysis using 10-
20% tris-tricine gels (Invitrogen, Carlsbad, CA) stained with Coomassie brilliant blue 
R250.  Edman degradation was performed on the cleaved protein to verify the N-
terminal sequence using G1000A Automated Protein Sequencer (Hewlett Packard, 
Albertville, MN).  The protein concentration of the rgpCCL5 preparation was 
determined by the Bradford protein assay (Bio-Rad, Richmond, CA) following 
manufacturer’s instructions.  Endotoxin levels were less 0.05ng/ug of recombinant 
protein using Limulus Amebocyte Lysate assay (Cape Cod Inc., Falmouth, MA).   
Animals.  Specific-pathogen-free, outbred, male and female Hartley guinea pigs 
from Charles River Breeding Laboratories, Inc. (Wilmington, MA), were used in this 
study.  They were housed in polycarbonate cages within an air-filtered environment 
under a 12 h light-dark cycle.  Food (Ralston Purina, St. Louis, MO) and tap water were 
supplied to the animals ad libitum.  All procedures were reviewed and approved by the 
Texas A&M University Laboratory Animal Care Committee. 
Isolation of macrophages.  Guinea pigs were euthanized by two 1.5 ml 
intramuscular injections of sodium pentobarbital (100mg/ml) (Sleepaway Euthanasia 
Solution; Fort Dodge Laboratories, Inc., Fort Dodge, IA).  To obtain peritoneal exudate 
cells (PEC), guinea pigs were injected intraperitoneally with 5 ml of 3% sodium 
thioglycollate (Becton Dickinson, Cockeysville, MD) four days before euthanasia.  
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Guinea pigs not injected with sodium thioglycollate were used as a source of resident 
peritoneal macrophages.  The abdominal and thoracic cavities were opened aseptically.  
The peritoneal cavity was flushed twice with 30ml of cold phosphate-buffered saline 
(PBS) with 10U/ml heparin and 2% FBS to obtain PEC or resident peritoneal 
macrophages.  Alveolar macrophages were obtained by exposing the trachea and 
inserting an 18-gauge cannula fixed to a 20 ml syringe.  The bronchoalveolar lavage 
(BAL) was performed by filling the lungs with cold 12mM lidocaine in PBS with 3% 
FBS as previously described (118).  Cells were pelleted by centrifuging at 380 × g for 10 
minutes.  These pellets were washed twice with RPMI-1640 medium without phenol red, 
supplemented with 10% FBS, 10µM 2-mercaptoethanol, and 2µM L-glutamine (RPMI 
complete medium).  The cells were resuspended in 1ml RPMI complete medium, and 
viable cells were enumerated on a hemacytometer by the trypan blue exclusion method.  
Cells from BAL were resuspended at 1×106 cells/ml, resident peritoneal cells at 1.5×106 
cells/ml, and PEC at a concentration of 5×106 cells/ml in RPMI complete medium. 
Chemotaxis assay for rgpCCL5 bioactivity.  Chemotaxis was performed using 
ChemoTx (Neuroprobe, Inc., Gaithersburg, MD) disposable chemotaxis systems 
containing 5µm pore size polycarbonate filters, following modified instructions from the 
manufacturer.  Briefly, PECs were resuspended in RPMI 1640 with 0.1% bovine serum 
albumin (RPMI-BSA) at a concentration of 5 × 106 cells/ml.  Dilutions of N-formyl-
Met-Leu-Phe (fMLP) (Sigma, St. Louis, MO) and rgpCCL5 were made in RPMI-BSA 
and added to the wells of a 96-well plate.  The polycarbonate filter was then placed on 
the plate and checked to ensure that the fluid in each well was in contact with the filter.  
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The cells were then added to the top of the filter in a 50µl volume containing 2.5 × 105 
cells/well.  Chemotaxis was performed at 37°C in 5% CO2 for 2 h.  Fluid on top of the 
filter was aspirated, and cold PBS with 0.5M EDTA was added and incubated at 4°C for 
30 min.  Cotton swabs were used to wipe off any cells remaining on the top of the filters.  
Plates were centrifuged for 430 × g for 10 minutes to dislodge any remaining cells bound 
to the underside of the filter.  The filter plate was removed and 150ul aspirated from 
each well.  A tetrazolium salt, 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide (MTT) (Sigma, St. Louis, MO), was added at 5mg/ml to each well and allowed 
to incubate for 2 h at 37°C in 5% CO2.  Plates were centrifuged at 140 × g for 5 min and 
supernatants were aspirated.  Warm lysis buffer (50% 2-2 Dimethylformamide and 20% 
SDS at pH 4.7) was added to each well and allowed to incubate for 4 h at 37°C and 5% 
CO2.  This colorimetric assay was then read at 570nm using a Dynatech MR5000 
automated plate reader and analyzed with Biolinx Software, version 2.1 (Dynatech 
Laboratories, Inc., Chantilly, VA). 
Macrophage stimulation.  Cells from the BAL and peritoneal cavity were 
plated on 96 well plates and allowed to adhere for 1.5 h at 37°C in 5% CO2 incubator.  
Nonadherent cells were aspirated and the adherent cells were washed with RPMI 
complete medium.  Adherent macrophages were stimulated with rgpCCL5 at different 
concentrations (1.35, 405, 1350, and 4050ng/ml) for 2 and 6 h.  To examine the priming 
effect of rgpCCL5 on the response to LPS, macrophages were pre-incubated with 
1350ng/ml rgpCCL5 for 2 h.  The cells were then exposed to LPS (10ng/ml) and 
samples were collected at 2 and 6 h post-LPS exposure.  At each time point, supernatants 
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were collected and stored at –70°C until analyzed for TNFα by the L929 bioassay, and 
total RNA was isolated using the RNeasy kit (QIAGEN, Valencia, CA) with the addition 
of Rnase-free DNase according to the manufacturer’s instructions.  
Real-time PCR on cytokine mRNA.  Reverse transcription was performed on 
1-5µg of total RNA using TaqMan Reverse Transcription Reagents (Applied 
Biosystems, Foster City, CA).  Negative controls were performed to ensure PCR 
amplification of cDNA was not due to contaminating genomic DNA.  RT-PCR analysis 
was performed on the cDNA using SYBR Green I (Applied Biosystems) following a 
previously published protocol (118).  Primer Express software (Applied Biosystems) 
was used to design the sequences for guinea pig hypoxanthine phosphoribosyltransferase 
(HPRT) (forward primer, AGGTGTTTATCCCTCATGGACTAATT; reverse primer, 
CCTCCCATCTCCTTCATCACAT) and guinea pig IL-1β (forward primer, 
GCCCAGGCAACAGCTCTC; reverse primer, 
GGAGTCTCTACCAGCTCAACTTGG).  The sequences for TNFα, CXCL8, and 
CCL2 primers were previously described (8, 118).  Real-time PCR was performed using 
the Applied Biosystems Prism 7700 sequence detector following the manufacturer’s 
instructions.  Results were expressed as fold induction of mRNA, which was determined 
by normalizing cytokine threshold cycle (Ct) values against HPRT values.  This was 
further normalized against samples from unstimulated cells at 0 h.   
L929 bioassay.  The concentration of bioactive TNFα protein in macrophage 
culture supernatants was measured by cytotoxicity on L929 fibroblasts (106).  Briefly, 
L929 cells were plated into 96-well plates in RPMI 1640 without phenol red 
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supplemented with 2µM L-glutamine, 100 U/ml of penicillin, 100µg/ml 
streptomycin/ml, and 2% FBS.  Serial two-fold dilutions of supernatants in 8µg/ml 
actinomycin D were added to each well and incubated for 20 h.  Cells were incubated for 
an additional 2 h at 37°C + 5% CO2 after the addition of WST-1 (6mM) / 1-
methoxymethyl phenazium methylsulfate (0.4mM) (Dojindo, Kumamoto, Japan).  The 
color development was halted with 1N H2SO4 and the optical densities were measured at 
OD450 and OD630.  Human recombinant TNFα (R&D Systems, Inc., Minneapolis, MN) 
was used to derive a standard curve and all samples were expressed as the 50% 
cytotoxicity value based on the standard curve.   
Statistical analysis.  Analysis of variance was used to determine statistical 
significance between mean differences of rgpCCL5-treated and untreated macrophages 
at a 95% confidence interval using Duncan post hoc analysis.  A two-tailed t-test was 
used to determine statistical significance at a 95% confidence interval between rgpCCL5 
prestimulated group and naive macrophages cultured with LPS.  The statistical tests 
were performed using SAS software (release 8.01; SAS Institute, Inc., Cary, NC).   
 
RESULTS 
Expression and bioactivity of recombinant guinea pig (rgp) CCL5.  Figure 1 
illustrates the expression and purification of rgpCCL5.  Large amounts of CCL5 were 
induced using low levels of IPTG (0.1mM) (Fig. 1A, lane 3).  The fusion protein was 
absent in the soluble fraction following cell lysis via French Press (fig. 1A, lane 5).  
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Inclusion bodies contained abundant rgpCCL5 (fig. 1A, lane 6), therefore, we treated the 
insoluble fraction with high concentrations of guanidine hydrochloride to solubilize the  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  SDS-PAGE analysis was used to trace rgpCCL5 through the expression and 
purification process.  (A) Lane 1, low molecular weight ladder; lane 2, uninduced total 
E. coli proteins; lane 3, cellular proteins from 0.1mM IPTG induced E. coli; lane 4, 
secreted proteins from induced cultures; lane 5, soluble proteins from E. coli lysate; lane 
6, insoluble proteins from E. coli lysate; lane 7, proteins after refolding; lane 8, 
purification of rgpCCL5 uncut from inclusion body proteins after reverse phase HPLC 
(B); lane 9, protein obtained from peak a (C); lane 10, mature rgpCCL5 purified from 
peak b (C) after reverse phase HPLC (recombinant gpCCL5).  Reverse phase HPLC 
displayed purification of rgpCCL5 with fusion peptide between 40-50% acetonitrile 
concentrations (B).  Following cleavage with Factor Xa, the fusion peptide and mature 
rgpCCL5 were separated by running solution over reverse phase-HPLC (C).  
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Figure 1 continued. 
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protein.  The separation of CCL5 from other E. coli proteins was achieved using reverse 
phase HPLC.  The fusion protein came off the C4 column as one peak between 45-50%  
acetonitrile concentrations (fig. 1B).  The protein was visualized as a distinct band at ~ 
14kDa on a 10-20% tris-tricine gel after SDS-PAGE analysis (fig. 1A, lane 8).  The 
fusion protein was then exposed to Factor Xa protease to obtain the mature form of 
gpCCL5.  Cleavage by the endoproteinase resulted in three bands on SDS-PAGE 
analysis (fig. 1A, lane 9) suggesting an uncut, improperly cut, and mature recombinant 
protein.  The amino acid compositions were determined using Edman degradation.  The 
improperly cut protein (~12 kDa) appeared to have a 5’- terminal amino acid sequence 
GSGMKE, which suggested the protein was improperly cleaved at the thrombin site 
found in the fusion peptide.  The ~8 kDa mature protein was sequenced and contained 
SPYASD hexa-peptide on the 5’ end, verifying it was the mature form of gpCCL5.  
Separation of these proteins was performed by retarding the acetonitrile gradient 
between 25-42% on reverse phase HPLC resulting in two distinct peaks (fig. 1C).  The 
first peak appeared to contain all three forms of the recombinant protein after SDS-
PAGE analysis (fig. 1A, lane 9).  However, the second peak contained mature CCL5 
alone at greater than 99% purity (fig. 1C peak b; fig. 1A, lane 10).   
      The bioactivity of rgpCCL5 was demonstrated in a chemotaxis assay using 
guinea pig PEC.  Figure 2 illustrates that significant PEC migration was induced by 
rgpCCL5 and the positive control, fMLP, compared to media alone.  In these 
experiments, cells were added to the upper chamber of a chemotaxis assay at a ratio of 
2.5 cells/pore.  The chemotactic agent was added to the lower chamber and after two  
 22
 
 
 
Figure 2:  Chemotactic properties of rgpCCL5 to PEC.  Chemotactic abilities of 
rgpCCL5 were assessed by determining the migration of guinea pig PEC in vitro to 
varying concentrations of recombinant protein and fMLP against media (RPMI + 
0.1%BSA) alone.  Cell migration was determined using the MTT viability assay after the 
cells were dislodged from the filters.  Results are displayed as the mean + SEM for three 
experiments, each containing quadruplicate wells per concentration tested.  * Significant 
differences (p < 0.05) were seen in migration with chemotactic agents compared to 
media alone, and **  (p < 0.05) displayed significance between rgpCCL5 concentrations 
using ANOVA.
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hours of incubation migration was detected using the MTT viability assay.  The 
migration was concentration-dependent, with 1350ng/ml being significantly greater than  
other concentrations tested (fig. 2).  At concentrations higher than 1350ng/ml, the 
chemotactic effect of gpCCL5 was diminished.    
Effect of rgpCCL5 on cytokine expression in macrophages.  Guinea pig 
resident peritoneal macrophages were exposed to varying concentrations of rgpCCL5, 
and the levels of mRNA of inflammatory cytokines and chemokines were assessed using 
real time PCR.  Figure 3 shows that the mRNA levels of two proinflammatory guinea 
pig cytokines, TNFα and IL-1β, were significantly enhanced at two hours post-rgpCCL5 
exposure compared to media alone (fig. 3A and 3B).  This effect was optimal at 
1350ng/ml of rgpCCL5 compared to the other concentrations tested.  After six hours, 
TNFα mRNA levels swiftly declined, but IL-1β levels tapered off to a lesser extent 
(fig.3A and 3B).  In comparison, LPS (10ng/ml) stimulation of resident peritoneal 
macrophages resulted in 42.62 + 11.95 and 11.21 + 4.57 fold induction for TNFα 
mRNA at 2 h and 6 h, respectively, and IL-1β mRNA increased to 6.87 + 0.64 and 5.99 
+ 1.32 fold induction at similar time intervals.   
      Sequences for the guinea pig chemokines are limited, however, CXCL8 and 
CCL2 are available (213, 214).  The kinetics of mRNA levels for these genes in response 
to rgpCCL5 mirrored the enhancement seen in TNFα and IL-1β mRNA.  At two hours 
post-exposure to rgpCCL5, both CXCL8 and CCL2 mRNA levels were significantly 
elevated compared to untreated cells.  The stimulatory effect was short-lived and at six 
hours these levels had declined (fig. 3C and 3D).  LPS (10ng/ml) was used as a positive  
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Figure 3:  Peritoneal macrophage activation by rgpCCL5 as evaluated by cytokine and 
chemokine mRNA expression.  Expression of TNFα (A), IL-β (B), CCL-2 (C), and 
CXCL-8 (D) mRNA was determined at two and six hours after rgpCCL5 (1.35, 405, 
1350, and 4050ng/ml) stimulation via real-time PCR.  Data represent the mean + SEM 
for 3-4 experiments with an asterisk representing significant differences (p < 0.05) 
between rgpCCL5 and media alone (RPMI + 10% FBS).  Double asterisks represent 
significance (p < 0.05) between different concentrations of rgpCCL5 at same time 
points.  Statistical analysis was performed using ANOVA.  
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Control, stimulating 7.22 + 2.78 and 7.44 + 3.3 CCL2 mRNA fold induction at 2 h and 6 
h, respectively, from unstimulated resident peritoneal macrophages.  CXCL8 mRNA  
fold induction levels were also heightened in LPS-treated cells to 23.26 + 5.00 and 18.48 
+ 7.16 at similar time points.   
      The diverse biological properties of different macrophage populations (70, 130, 
168, 205) prompted us to extend our studies of the stimulatory effect of gpCCL5 to 
alveolar macrophages, a cell type which we have studied previously and which is 
relevant to our focus on the pathogenesis of pulmonary tuberculosis in the guinea pig 
model (118, 215).  Figure 4 illustrates mRNA levels for TNFα, IL-1β, CCL2, and 
CXCL8 in alveolar macrophages stimulated with rgpCCL5.  At 1350ng/ml, rgpCCL5 
significantly enhanced mRNA levels of TNFα and IL-1β compared to all other 
concentrations tested (fig. 4A and 4B).  At six hours, these levels fell in a manner similar 
to that observed in resident peritoneal macrophages.  However, this kinetic pattern was 
not repeated with alveolar macrophages stimulated with LPS (10ng/ml).  TNFα mRNA 
fold induction levels increased from 2 h (67.1 + 33.53), to 6 h (108.45 + 27.02), and IL-
1β mirrored similar patterns with mRNA fold induction levels increasing from 28.38 + 
11.55 to 112.98 + 39.95 at 2 h and 6 h, respectively.  Chemokines were evaluated in 
alveolar macrophages in response to rgpCCL5 stimulation.  CXCL8 mRNA levels were 
enhanced significantly with rgpCCL5 at 1350ng/ml in alveolar macrophages at two and 
six hours following stimulation, a kinetic pattern which differed from peritoneal 
macrophages.  Fold induction levels of CXCL8 mRNA from LPS (10ng/ml) stimulated 
alveolar macrophages were 52.92 + 23.34 at 2 h, and 234.83 + 88.28 at 6 h.  CCL2  
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Figure 4:  Alveolar macrophage activation by rgpCCL5 as determined by enhanced 
mRNA levels of cytokine and chemokine genes.  Stimulation was assessed at two and 
six hours for TNFα (A), IL-β (B), CCL-2 (C), and CXCL-8 (D) mRNA using real-time 
PCR.  Data represent the mean + SEM of three experiments.  Double asterisks represent 
significance (p < 0.05) between rgpCCL5 concentrations and media alone.  Significance 
was determined by ANOVA analysis.        
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MRNA expression was not increased significantly by stimulation with rgpCCL5 
compared to media alone, although mRNA levels were higher at all concentrations 
tested.  In contrast, LPS stimulated alveolar macrophages produced elevated levels of 
CCL2 mRNA at 2h (5.33 + 1.21), and at 6 h (14.15 + 3.95). 
In figure 5, bioactive TNFα levels were assessed in macrophages treated with 
rgpCCL5.  Resident peritoneal macrophages stimulated with rgpCCL5 displayed 
significantly enhanced levels of bioactive TNFα protein at both two and six hours 
following stimulation with all concentrations of rgpCCL5 tested (1.35, 405, 1350, and 
4050ng/ml) compared to media alone (fig. 5A).  However, in alveolar macrophages 
exposed to the same stimulants, TNFα protein levels followed the same narrow 
rgpCCL5 concentration kinetics as seen in mRNA levels with significantly higher levels 
of protein at two hours in response to 1350ng/ml rgpCCL5 compared to all other lower 
concentrations tested (fig. 5B).  At six hours, this pattern was repeated and 1350ng/ml 
rgpCCL5 induced significantly higher TNFα protein levels than all other concentrations 
tested (fig. 5B).                      
Effect of CCL5 prestimulation on the responses of macrophages to LPS.  
Figure 6 shows the ratio of mRNA levels for TNFα, IL-1β, CCL2, and CXCL8 in 
resident peritoneal macrophages prestimulated with rgpCCL5 (1350ng/ml) for two hours 
and then exposed to a low concentration of LPS (10ng/ml) for two or six hours.  Two 
hours and six hours post-LPS stimulation, TNFα mRNA was diminished by nearly 40% 
in peritoneal macrophages prestimulated with rgpCCL5 compared to mRNA levels in 
cells not exposed to rgpCCL5 (fig. 6A).  CCL2 mRNA was modestly enhanced (30%
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Figure 5:  TNFα protein levels from guinea pig peritoneal and alveolar macrophages 
stimulated with rgpCCL5.  The L929 bioassay was used to determine TNFα protein 
concentrations in alveolar (A) and peritoneal (B) macrophages stimulated with rgpCCL5 
for two and six hours.  Data represent mean + SEM from 3-4 experiments.  Significance 
(p < 0.05) of rgpCCL5 compared to media alone is depicted by an asterisk.  Significance 
(p < 0.05) between concentrations is denoted as two asterisks.  Statistical analysis was 
performed using ANOVA.
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Figure 6:  Regulation of LPS-induced cytokine and chemokine mRNA expression in 
guinea pig peritoneal macrophages by pretreatment with rgpCCL5.  Expression of TNFα 
(A), IL-β (B), CCL-2 (C), and CXCL-8 (D) mRNA was assessed by real-time RT-PCR.  
Cells were pretreated with 1350ng/ml rgpCCL5 for two hours, and then stimulated with 
LPS (10ng/ml) for two or six hours.  Results are expressed as mean + SEM of the ratios 
of mRNA in rgpCCL5-pretreated over untreated cells of 3-4 experiments.  Significance 
(p < 0.05) between ratios at different time points was determined using Student’s t test 
and is denoted by an asterisk.
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Increased) in the rgpCCL5-pretreated macrophages at two hours post-LPS stimulation,  
however, by six hours the levels had fallen significantly (fig. 6C).  Levels of mRNA for 
IL-1β and CXCL8 were minimally affected by rgpCCL5 pretreatment at two hours, but 
at six hours post-LPS stimulation they were modestly diminished in rgpCCL5 pretreated 
cultures (fig. 6B and D).  
      Since the effect of priming with CCL5 on the responses of different macrophage 
populations to LPS was of interest, alveolar macrophages were pretreated with rgpCCL5 
in a similar fashion.  In figure 7, TNFα mRNA levels were reduced by 40% at two hours 
post-LPS stimulation in rgpCCL5 pretreated macrophages compared to untreated LPS-
stimulated alveolar macrophages (fig. 7A).  However, IL-1β, CCL2, and CXCL8 mRNA 
levels displayed a different trend.  At two hours, rgpCCL5 pretreated alveolar 
macrophages had slightly higher mRNA levels than alveolar macrophages not exposed 
to rgpCCL5.  This trend was reversed at six hours post LPS-stimulation when all 
rgpCCL5 pretreated macrophages expressed lower mRNA levels compared to LPS 
alone.  This change in mRNA expression levels between two and six hours is significant 
in pretreated alveolar macrophages for CXCL8 (p<0.02).   
      Figure 8 shows the concentrations of TNFα protein produced between alveolar 
and peritoneal macrophages pretreated with rgpCCL5 or untreated, following 
stimulation with LPS.  Resident peritoneal macrophages produced significantly more 
bioactive TNFα protein levels at two hours post-LPS stimulation following pretreatment 
with rgpCCL5 (fig. 8A).  However, this pattern was reversed at six hours with TNFα 
levels were unaltered in rgpCCL5 pretreated macrophages compared to the enhanced
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Figure 7:  Regulation of LPS-induced cytokine and chemokine mRNA expression in 
guinea pig alveolar macrophages by pretreatment with rgpCCL5.  Expression of TNFα 
(A), IL-β (B), CCL-2 (C), and CXCL-8 (D) mRNA was assessed by real-time RT-PCR.  
Cells were pretreated with 1350ng/ml rgpCCL5 for two hours, and then stimulated with 
LPS (10ng/ml) for two or six hours.  Results are expressed as mean + SEM of the ratios 
of mRNA in rgpCCL5-pretreated over untreated cells of 3-4 experiments.  Significance 
(p < 0.05) between ratios at different time points was determined using Student’s t test 
and is denoted by an asterisk. 
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Figure 8:  Regulation of LPS-induced TNFα protein production by rgpCCL5- 
pretreatment in peritoneal and alveolar macrophages.  Alveolar (A) and peritoneal (B) 
macrophages were pretreated with 1350ng/ml rgpCCL5 for two hours followed by 
stimulation with 10ng/ml LPS for two or six hours.  Supernatants were assessed for 
TNFα protein levels using the L929 bioassay.  Data in A and C are the mean + SEM of 
TNFα protein concentrations (ng/ml) from four experiments.  The ratios of TNFα 
protein concentration of rgpCCL5-pretreated/untreated cells are represented in B 
(peritoneal) and D (alveolar).  An asterisk represents significance differences (p < 0.05) 
between LPS stimulated macrophages from rgpCCL5 pretreated versus LPS alone at 
similar time points.  A double asterisk denotes significance (p < 0.005) between TNFα 
protein production at two versus six hours with the same stimulus (fig. 8A and C) or 
significance between the average ratios (LPS+rgpCCL5/LPS) of two and six hours (fig. 
8B and D).  Statistics were performed using the Student’s t test.
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Expression in macrophages exposed to LPS alone.  This trend was present in alveolar  
macrophages as well but, due to the variability between animals, statistical significance 
was not reached (fig. 8C).  Both macrophage populations displayed minimal alterations 
in TNFα protein levels at six hours post-LPS stimulation in cells primed with rgpCCL5 
(1350ng/ml) compared to two hours (fig. 8A and 8C).  A significant difference was seen 
when comparing the ratios TNFα protein in rgpCCL5 pretreated versus untreated 
macrophages following LPS stimulation.  The ratio (treated/untreated) at two hours was 
significantly greater than at six hours (fig. 8B and 8D), suggesting CCL5 had the ability 
to enhance TNFα protein production immediately, however, production declined 
thereafter.  This trend was seen in both macrophage populations.      
 
 
DISCUSSION 
 
In this study, we tested the ability of rgpCCL5 to enhance the proinflammatory 
responses in guinea pig macrophages.  The current dogma suggests that CCL5 attracts 
leukocytes to the site of inflammation via signaling through seven transmembrane G-
coupled protein receptors (12, 169) and glycosoaminoglycan (GAG) receptors (157).  It 
has been shown that the interaction of CCL5 with GAG on T cells results in prolonged 
calcium influx (14) in response to signaling via protein tyrosine kinases (33).  This 
suggests CCL5 may have the ability to activate many cellular responses due to the 
promiscuity in receptor binding and the activation of numerous signaling pathways.   
      Our data show that rgpCCL5 significantly enhanced IL-1β and TNFα mRNA 
levels (fig. 3A, 3B, 4A, and 4B), as well as TNFα protein production (fig. 5A and B), 
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compared to media alone in both resident peritoneal and alveolar macrophages isolated 
from guinea pigs.  This is the first time CCL5 has been shown to stimulate the 
expression of both proinflammatory cytokines in tissue specific macrophages.  The 
ability of CCL5 to enhance IL-1β mRNA is in agreement with a previous study looking 
at human nonadherent monocytes exposed to recombinant CCL5 (113).  Human 
recombinant CCL5 alone, at varying concentrations, was able to significantly heighten 
IL-1β mRNA levels in nonadherent human monocytes (113).  However, in that study, 
increased IL-1β protein synthesis was not seen.  Other studies have shown that 
adherence enhances IL-1β mRNA in macrophages, however, this priming results in 
earlier and enhanced IL-1β synthesis in human peripheral blood mononuclear cells 
stimulated with LPS (176).  Due to the absence of reagents for the guinea pig, IL-1β 
protein levels could not be measured in our study. 
      For the first time in any species, enhanced expression and secretion of bioactive 
TNFα was documented when resident peritoneal and alveolar macrophages were 
incubated with rgpCCL5 (fig. 3A, 4A, 5A, and 5B).  These findings contrast with the 
previous report in which no increase in TNFα protein levels were observed in 
nonadherent human monocytes treated with CCL5 (113).  This apparent contradiction 
may be related to species or macrophage differences.  The previous study used human 
nonadherent monocytes compared to the adherent guinea pig resident tissue 
macrophages examined in this study.  Another plausible explanation may be that our 
macrophages were slightly activated due to adherence to plastic, which may have 
enhanced the stimulatory effect of rgpCCL5 on macrophage production of TNFα.  The 
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study of macrophages which have been slightly activated by adherence may mimic what 
is occurring in vivo, since these macrophages are migrating along chemokine 
concentration gradients to arrive at the site of inflammation.  It has been shown 
previously that cytokines, including TNFα, IL-1β, and/or IFNγ, enhance CCL5 mRNA 
and/or protein in human synovial fibroblasts (159), human endothelial cells (122), 
murine macrophages (212), and human monocytes (123).  These data suggest that CCL5 
and cytokines may cooperate to enhance each other’s expression.    
      Stimulation with rgpCCL5 significantly enhanced CCL2 mRNA expression by 
resident peritoneal macrophages, but not alveolar macrophages (fig. 3C and 4C).  Levels 
of CXCL8 mRNA were increased significantly in both macrophage types by stimulation 
with rgpCCL5 (fig. 3D and 4D).  These chemokines are chemotactic for T lymphocytes 
(139), neutrophils (112), and monocyte/macrophages (163, 188).  CCL2 has previously 
been shown to induce IL-1 and IL-6 protein in human monocytes (87), and to enhance 
Th2 polarization in mice (47).  CXCL8 has been suggested to play a role in providing 
protection against infection because enhanced levels of expression are observed in 
vaccinated compared to naive animals (118).  In a study where the IL-8 receptor 
(CXCR2) was knocked out, the mice were more susceptible to gastric and acute 
systemic candidiasis (17, 120).  A previous study showed that CCL2 and CXCL8 mRNA 
levels were enhanced in human nonadherent monocytes when exposed to CCL5 alone, 
and CCL2 protein levels mimicked mRNA expression (113).  In our studies, CCL5 
enhanced both CXCL8 and CCL2 mRNA levels.  These results suggest CCL5, while 
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attracting the macrophages to the site of infection, is priming macrophages for an 
encounter with microbes by enhancing cytokine and chemokine expression levels.   
      Differences observed in this study between peritoneal and alveolar macrophages 
have also been documented with regard to a variety of biological responses (53, 70, 82, 
192, 201).  However, very few studies have looked at the response of different resident 
macrophage populations to chemokines alone.  Our results show that alveolar 
macrophages were less sensitive to stimulation with rgpCCL5 than peritoneal 
macrophages.  Alveolar macrophages displayed a significant enhancement in TNFα, IL-
1β, and CXCL8 mRNA expression (fig. 4) and TNFα protein (fig. 5B) only when 
stimulated with 1350ng/ml rgpCCL5 compared to media alone.  In contrast, peritoneal 
macrophages displayed significant enhancement of TNFα, IL-1β, CCL2, and CXCL8 
mRNA expression (fig. 3) and TNFα protein (fig. 5A) at lower concentrations of 
rgpCCL5.  This might be due to different expression levels of CCL5 receptors and/or 
differences in signal transduction pathways.  Differences between macrophage 
populations were seen also in the degree of stimulation of chemokine mRNA levels post-
rgpCCL5 exposure.  CCL2 mRNA was not significantly enhanced in alveolar 
macrophages exposed to rgpCCL5 (fig. 4C), whereas it was significantly increased in 
peritoneal macrophages (fig. 3C).  Also, the kinetics of CXCL8 mRNA alterations 
differed between the two cell types.  Alveolar macrophages expressed increasing levels 
of CXCL8 mRNA at 6h compared to 2h, in contrast to peritoneal macrophages in which 
expression of CXCL8 mRNA was diminished at 6hr.  These data contribute to a better 
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understanding of the variation between different resident macrophage populations in 
terms of their responses to CCL5.   
It has been shown in previous studies that LPS induces the expression of many 
chemokines, including CCL5, in vitro (37, 93, 99) and in vivo (99).  In an attempt to 
better understand the effect of CCL5 exposure on the response of macrophages to LPS, 
alveolar and peritoneal macrophages were pretreated with rgpCCL5 and then stimulated 
with low levels of LPS.  We observed a significant reduction in the ratio (LPS + 
rgpCCL5/ LPS) of CCL2 mRNA in peritoneal macrophages (fig. 6C), and CXCL8 
mRNA in alveolar macrophages (fig. 7D) between two and six hours.  TNFα exhibited 
diminished levels of mRNA at 2 h post-LPS stimulation in the rgpCCL5 pretreated 
macrophages (fig. 6A and 7A), however, the bioactive TNFα protein levels appeared 
slightly enhanced at 2 h followed by a reduction at 6h (fig. 8).  One explanation for these 
findings might be the presence of endogenous TNFα produced by the macrophages 
before exposure to LPS.  We have shown that CCL5 alone can induce bioactive TNFα 
protein as early as two hours post-CCL5 exposure (fig. 5).  This production, plus the 
additional TNFα produced by macrophages upon activation by LPS, might result in the 
production of the immunoregulatory cytokine, IL-10.  Previous studies have shown that 
TNFα alone induces IL-10 expression and production in human monocytes (208) and 
enhances IL-10 secretion when the cells are co-cultured with LPS (64, 156, 208).  IL-10 
suppresses many proinflammatory cytokines and chemokines in human monocytes, 
including TNFα, IL-1β, and CXCL8 (44).  Human monocytes incubated with IL-10 and 
LPS exhibited a profound reduction in TNFα production compared to LPS alone (64) 
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and this effect appeared to be dependent on adherence to plastic (153).  Pretreatment of 
monocytes with TNFα has resulted in partial cross-tolerance to LPS by suppressing 
ERK phosphorylation and increasing NFĸB p50 homodimers (59), which are associated 
with LPS-tolerance.  The topic of TNFα induced LPS tolerance has resulted in numerous 
contradicting publications suggesting both the inability and ability to induce cross-
tolerance to LPS (59, 64, 66, 133).  We plan to investigate the controversial role of 
endogenous TNFα by blocking TNFα activity in the cultures using anti-rgpTNFα 
antiserum.  The contribution of IL-10 to the CCL5-induced hyporesponsiveness of 
macrophages to LPS will have to wait until rgpIL-10 and anti-gpIL-10 are available.   
Another plausible explanation for the altered cytokine expression in CCL5 
pretreated macrophages following LPS exposure may be the ability of IL-1β to induce 
LPS tolerance.  In our experiments, IL-1β mRNA was induced within 2h of CCL5 
treatment of both alveolar and peritoneal macrophages (Fig. 3B and 4B).  Previous 
experiments have shown that IL-1β is regulated at the transcriptional and translational 
levels and that two signals are needed for IL-1β protein production (176).   Due to the 
lack of guinea pig reagents, IL-1β protein levels were not assessed.  However, it has 
been demonstrated that adherence of macrophages alone induces IL-1β mRNA levels 
(176) and stimulation of human nonadherent monocytes with CCL5 triggers IL-1β 
mRNA synthesis (113).  Pretreatment of macrophages with IL-1β has resulted in LPS 
tolerance in many studies (9, 59, 133).  This may be the result of common signaling 
intermediates between the LPS receptor (TLR4) and IL-1 receptor (IL-1R), such as 
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MyD88, IL-1R-associated kinase (IRAK), TNFR-associated factor-6, and NF-ĸB-
inducing kinase (134).  Another explanation for this cross-tolerance involves the ability 
of IL-1β to down-regulate TLR4 expression in peritoneal macrophages (9).  It has also 
been shown that TNFα and IL-1β synergistically enhance LPS-induced production of 
the immunoregulatory cytokine, IL-10 (64).  These data suggest that IL-1β and TNFα 
are induced in guinea pig macrophages by pretreatment with rgpCCL5 and lead to a state 
of tolerance when macrophages are exposed subsequently to LPS.       
       A novel direct role of CCL5 may account for the altered cytokine expression in 
CCL5 pretreated macrophages.  Interactions between the signal transduction pathways 
elicited by CCL5 following engagement with seven transmembrane G protein-coupled 
receptors (CCR1, 3, 4, and 5) and glycosaminoglycans (GAG) might affect the ability of 
LPS to induce exceedingly high levels of cytokines and chemokines.  A previous study 
induced nonadherent monocytes with rhCCL5 and observed the upregulation of 114 
genes involved in various biological activities (113).  Many of these genes have not been 
analyzed for their ability to alter the response of the cells to LPS.       
These results suggest that CCL5 may directly or indirectly regulate the host 
phagocytic cell responses to prevent uncontrollable release of dangerous concentrations 
of proinflammatory cytokines.  We plan on further elucidating the mechanisms by which 
CCL5 pre-treatment alters macrophage responses to bacterial products, and the role it 
may play in host-pathogen interactions, especially in the response of the guinea pig to 
Mycobacterium tuberculosis.
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CHAPTER III 
ACTIVATION OF ANTI-MYCOBACTERIAL FUNCTIONS IN 
MACROPHAGES AND LYMPHOCYTES BY rgpCCL5 
 
INTRODUCTION 
Tuberculosis (TB) has continued to plague mankind for millennia, and 
Mycobacterium tuberculosis currently infects over one third of the world’s population 
(56).  The development of new vaccines is in great demand due to the varying efficacy 
of the current BCG vaccine (13, 38, 73).  Designing an improved TB vaccine will 
require a better understanding of the host immune response to TB.  Currently, the guinea 
pig is an excellent model in which to test new tuberculosis vaccines because of the 
degree of protection BCG provides against pulmonary and disseminated tuberculosis in 
this species (186), and the similarities of guinea pigs to humans with regard to similar 
delayed type hypersensitivity (PPD) reactions, pulmonary physiology, granuloma 
composition and structure, and the ability to infect with a few bacilli via aerosolized 
droplet nuclei (16, 127).    
 Chemokines play an important role in eliciting a protective immune response 
against M. tuberculosis by participating in the formation of a well-defined and localized 
granuloma (35, 181), contributing to a delayed type hypersensitivity reaction (34, 35, 48, 
121), attracting protective inflammatory cells to the site of infection (12, 27, 166, 209), 
and assisting in the differentiation of CD4+ T cells into a Th1 phenotype (54, 125, 217).  
The beta-chemokine, CCL5 (RANTES), is unique among the chemokines because of its 
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diverse biological activities.  The role of CCL5 during the inflammatory response has 
been elucidated in cell lines and animal models.  At low concentrations (ng/ml), CCL5 is 
chemotactic to numerous leukocytes, including eosinophils (4), CD4+ and CD8+ T 
lymphocytes (52, 166, 209), and monocyte/macrophages (12, 27, 142, 198, 209).  It has 
also been demonstrated that CCL5 not only attracts these cell types to the foci of 
infection, but activates them as well.  At high CCL5 concentrations (µg/ml), such as 
those most likely found at the foci of infection, T lymphocytes have been shown to be 
activated, resulting in IL-2 (121, 193) and IFNγ production (110, 121), as well as 
proliferation (14, 121, 193) .  Previous studies have demonstrated the induction of 
reactive oxygen species (ROS) in eosinophils in response to CCL5 (36, 79, 91, 170).  
However, the chemotactic properties of CCL5 on eosinophils is diminished in the 
presence of peroxynitrite (171), suggesting reverse roles of CCL5 at high concentrations 
in eosinophils.  The use of CCL5 as a gene adjuvant in DNA vaccines resulted in 
enhanced cytotoxic T lymphocyte activity and proliferation (95).  Furthermore, M. 
tuberculosis viability inside human alveolar macrophages was increased when the cells 
were co-cultured with anti-human CCL5 (174).   
In these studies, we elucidated the activation of guinea pig immune cells by 
gpCCL5.  We examined the ability of CCL5 to modulate PPD-induced T lymphocyte 
proliferation, to affect the production of reactive oxygen species by macrophages in 
response to M. tuberculosis infection, and to alter M. tuberculosis viability within 
macrophages.  
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MATERIALS AND METHODS 
Mycobacteria preparation.  Mycobacterium tuberculosis H37Rv (ATCC 
27294; American Type Culture Collection, Manassas, VA) and H37Ra (ATCC 25177) 
stored at –80°C were rapidly thawed, vortexed, and sonicated for 60s with an Ultrasonics 
sonicator (Heat Systems-Ultrasonics, Inc., Plainview, NY) at an output setting of 8.0 to 
remove clumps.   
Animals and vaccination.  Specific-pathogen-free, outbred, male and female 
Hartley guinea pigs from Charles River Breeding Laboratories, Inc. (Wilmington, MA) 
were housed in polycarbonate cages within an air-filtered environment under a 12 h 
light-dark cycle.  Food (Ralston Purina, St. Louis, MO) and tap water were supplied to 
the animals ad libitum.  Vaccination of guinea pigs was performed via intradermal 
injection of 0.1ml (103 CFU) of viable Mycobacterium bovis BCG (Danish 1331 strain, 
Statens Seruminstitut, Copenhagen, DK) into the left inguinal region.  All procedures 
were reviewed and approved by the Texas A&M University Laboratory Animal Care 
Committee.   
Necropsy and macrophage isolation.  Guinea pigs were euthanized by two 1.5 
ml intramuscular injections of sodium pentobarbital (100mg/ml) (Sleepaway Euthanasia 
Solution; Fort Dodge Laboratories, Inc., Fort Dodge, IA).  The abdominal and thoracic 
cavities were opened aseptically and resident peritoneal macrophages were obtained by 
flushing the peritoneal cavity twice with 30ml of cold sterile phosphate-buffered saline 
(PBS) with 10U/ml heparin and 2% fetal bovine serum (FBS) (Atlanta Biologicals, 
Norcross, GA).  Alveolar macrophages were obtained by exposing the trachea and 
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inserting an 18-gauge cannula fixed to a 20 ml syringe.  The bronchoalveolar lavage 
(BAL) was performed by filling the lungs with cold 12mM lidocaine in PBS with 3% 
FBS as previously described (118).  Cells were pelleted by centrifuging at 320 × g for 15 
minutes at 4°C.  These pellets were washed once with cold PBS.  The cells were 
resuspended in 1ml of RPMI-1640 medium with phenol red (Irvine Scientific, Santa 
Anna, CA), 10µM 2-mercaptoethanol, 2 µM L-glutamine, 100 U/ml of penicillin, 
100µg/ml of streptomycin, and 10% heat-inactivated FBS (RPMI 1640 complete 
medium).  Viable cells were enumerated on a hemacytometer by Trypan blue exclusion 
(Gibco Life Technologies, Grand Island, NY).  Cells from BAL were resuspended at 
1×106 cells/ml and resident peritoneal macrophages at 2×106 cells/ml.  Macrophage 
populations were added at 200µl/well in a 96-well polystyrene plate for 2 h.  
Nonadherent cells were removed by washing with warm RPMI 1640 complete medium.   
Preparation of splenocytes.  Spleens were removed aseptically from the 
peritoneal cavity and placed in RPMI-1640 complete medium.  Spleens were 
homogenized and erythrocytes were lysed with ACK lysis buffer (0.14M NH4Cl, 1.0mM 
KHCO3, 0.1mM Na2EDTA [pH 7.2 – 7.4]).  Splenocytes were washed twice and 
resuspended in RPMI 1640 complete medium at a concentration of 2 X 106 cells/ml 
determined by excluding dead cells using Trypan blue exclusion and enumerating 
splenocytes on a hemacytometer.  Splenocytes were added to a 96-well polystyrene plate 
in a volume of 100µl.       
Macrophage stimulation and hydrogen peroxide detection.  Resident 
peritoneal and alveolar macrophages from BCG-immunized or non-immunized guinea 
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pigs were rested for 18 h and infected with an attenuated strain of M. tuberculosis 
H37Ra at varying MOIs with added rgpCCL5, rgpTNFα (105), rabbit anti-gpTNFα 
(105), or RPMI 1640 complete media alone for varying periods of time.  Media was 
removed and replaced with 100µl of H2O2 assay solution (0.2 ml phenol red stock 
(28mM), 0.2 ml horse-radish peroxidase (1000U/ml) (Sigma, St. Louis, MO), and 9.6ml 
Hanks balanced salt solution without phenol red (Sigma)) and incubated at 37°C in 5% 
CO2 for 90 minutes.  The reaction was interrupted by the addition of 10µl of 1N NaOH 
to each well.  Absorbance was measured using a Dynatech MR5000 automated plate 
reader (Dyantech Laboratories, Inc., Chantilly, VA) at 630nm after 3 minutes.  A 
standard curve was derived using two-fold dilutions of H2O2 (0.78 – 100µM) to quantify 
H2O2 concentrations in samples.     
Lymphoproliferation.  Splenocytes were incubated with rgpCCL5 (see Chapter 
II for preparation) or rabbit anti-rgpCCL5 (see Chapter V for preparation) with or 
without PPD (12.5 or 25 µg/ml) or ConA for different time periods.  [H3] thymidine was 
added at 1 µCi/well for the final 24 h of incubation.  Splenocytes were harvested onto 
glass fiber filters, and proliferation was determined by the number of counts per minute 
with a liquid scintillation counter (LS8000; Beckman Instruments, Inc., Fullerton, CA).  
M. tuberculosis viability assay.  Resident alveolar and peritoneal macrophages 
from naive and BCG-vaccinated guinea pigs were pretreated with rgpCCL5, rabbit anti-
rgpCCL5, or media alone and infected with M. tuberculosis H37Rv (MOI 1:5) for 2 h at 
37°C in 5% CO2.  Extracellular bacteria were aspirated and fresh RPMI 1640 medium 
with 10µM 2-mercaptoethanol, 2 µM L-glutamine, 10% FBS, and gentamycin 
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(200µg/ml) was added to each well for varying periods of time.  [3H] uracil at 1 µCi/well 
was added during the last 24 h of incubation.  After each time interval, live M. 
tuberculosis was heat-killed by incubating at 80°C for 30 minutes.  Macrophages were 
harvested onto glass fiber filters, and M. tuberculosis proliferative activity was 
determined by the number of counts per minute with a liquid scintillation counter.      
 
RESULTS  
Effect of gpCCL5 on hydrogen peroxide production.  Figure 9 illustrates the 
effect of rgpCCL5 and rgpTNFα on H2O2 production in alveolar and peritoneal 
macrophages isolated from naive and BCG-vaccinated guinea pigs.  Figure 9A 
demonstrates the inability of rgpTNFα or rgpCCL5 to induce H2O2 in rested resident 
peritoneal or alveolar macrophages.  In figure 9B, attenuated M. tuberculosis H37Ra 
(MOI 5:1) was shown to induce H2O2 after only 90 minutes of incubation.  The 
pretreatment of macrophages with rgpTNFα (50ng/ml) or rgpCCL5 (1,250-
12,500ng/ml) for 2 h before infection did not affect significantly H2O2 production from 
M. tuberculosis H37Ra infected macrophages.  It was demonstrated that infection with 
M. tuberculosis H37Ra was not altered in the presence of anti-rgpTNFα during the 90-
minute infection.  Macrophages were also studied following infection for longer periods 
of time (24 h and 48 h), however, H2O2 production appeared to be greater during earlier 
time points (data not shown). 
The effect of rgpCCL5 on M. tuberculosis viability in macrophages.  Previous 
studies have demonstrated increased viability of M. tuberculosis in the presence of anti- 
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Figure 9:  The effect of rgpTNFα and rgpCCL5 on H2O2 production in macrophages 
infected with M. tuberculosis.  Resident alveolar and peritoneal macrophages were 
isolated from BCG-vaccinated guinea pigs and stimulated with rgpTNFα (50ng/ml), 
rabbit anti-rgpTNFα (diluted 1:2000), or rgpCCL5 (1250ng/ml or 12.5ug/ml) for 2 h 
followed by the addition of H2O2 assay medium for 90 minutes (A).  The effect of 
rgpTNFα and rgpCCL5 on H2O2 production in macrophages infected with M. 
tuberculosis H37Ra (MOI 5:1) is displayed in panel B.  Cells were pretreated with 
rgpTNFα or rgpCCL5 for 2 h, or co-cultured with anti-rgpTNFα and infected with 
H37Ra for 90 minutes in H2O2 assay medium.  H2O2 was assessed as discussed in 
Materials and Methods.  Results are presented as the mean + SD of triplicate wells from 
one experiment.     
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Human CCL5 (174).  Figure 10 illustrates the effect of gpCCL5 on virulent M. 
tuberculosis viability within macrophages.  Macrophages isolated from BCG-vaccinated 
guinea pigs were infected with M. tuberculosis H37Rv (MOI 1:5) for 7 days.  In figure 
10A, it appears CCL5 does not affect M. tuberculosis viability within alveolar 
macrophages.  Resident peritoneal macrophages appeared to limit M. tuberculosis 
replication in the presence of rgpCCL5 (1250ng/ml and 62.5µg/ml) (Fig. 10B).  It is also 
apparent that high concentrations of anti-rgpCCL5 IgG has an inhibitory effect against 
bacterial viability in peritoneal macrophages. 
   Figure 11 demonstrates the difference in M. tuberculosis viability within 
macrophages obtained from BCG-vaccinated versus naive guinea pigs.  Macrophages 
were infected with M. tuberculosis H37Rv (MOI 1:1 or 1:5) for 7 days.  Pretreatment of 
infected macrophages with rgpCCL5 (1250ng//ml and 12.5µg/ml) for 2 h or co-culture 
with rgpCCL5 (12.5µg/ml) did not seem to affect bacterial viability.  The co-culture of 
infected macrophages with anti-rgpCCL5 IgG (1:50) resulted in no differences.  
However, alveolar macrophages isolated from BCG-vaccinated guinea pigs had an 
enhanced ability to control M. tuberculosis growth in vitro compared to macrophages 
isolated from naive animals, regardless of the alteration of CCL5 activity in the cultures.      
Effect of rgpCCL5 on splenocyte proliferation.  Figure 12 demonstrates the 
effect of rgpCCL5 on splenocyte proliferation .  Figure 12A suggests rgpCCL5 has a 
minimal effect on spontaneous proliferation of splenocytes taken from naive guinea pigs 
and cultured for 2 or 3 days.  Peak splenocyte proliferation was apparent with 1ug/ml of 
rgpCCL5 with levels ~ 1.5 fold higher than media alone.  At higher concentrations, this  
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Figure 10:  The effect of rgpCCL5 on M. tuberculosis viability within macrophages 
isolated from BCG-vaccinated guinea pigs.  Alveolar macrophages (A) and resident 
peritoneal macrophages (B) were stimulated with rgpCCL5 (125ng/ml – 1250ug/ml) or 
anti-CCL5 (1:100 and 1:1000) and infected with M. tuberculosis H37Rv (MOI 1:5) for 7 
days with 1µCi/well of [3H] uracil being added 24 h before harvesting the cells.  Cells 
were harvested onto glass fiber filters and read with a liquid scintillation counter.  Each 
set of data represent mean + SEM of triplicate wells from one experiment.
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Figure 11.  The effect of BCG-vaccination status on M. tuberculosis viability within 
alveolar macrophages.  Alveolar macrophages were isolated from BCG-vaccinated and 
naive guinea pigs and either pretreated with rgpCCL5 (1250ng/ml or 12.5ug/ml) for 2 h 
or co-cultured with CCL5 (12.5ug/ml), anti-CCL5, guinea pig IgG, or media and 
infected with M. tuberculosis H37Rv (MOI 1:5 and 1:1) for 7 days.  During the last 24 h 
of incubation 1µCi/well of [3H] uracil was added and cells were harvested onto glass 
fiber filters.  Radioactivity was quantitated using a liquid scintillation counter and the 
results are displayed as counts per minute (cpm).  Results are representative of the means 
+ SEM of triplicate wells from one experiment. 
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Figure 12:  The effect of rgpCCL5 on splenocyte proliferation.  In panel A, splenocytes 
were obtained from naive guinea pigs and stimulated with rgpCCL5 (125ng/ml – 
62.5µg/ml) for 2 or 3 days.  Panel B displays proliferation from splenocytes obtained 
from BCG-vaccinated animals and stimulated with rgpCCL5 for 4 days.  During the last 
6 h (panel A) or 24 h (panel B) of incubation, 1 µCi/ml [3H] thymidine was added to 
each well.  Cells were harvested and proliferative activity determined by counts per 
minute (cpm).  Results are representative of the mean + SEM of triplicates per treatment 
group from one experiment.  
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Effect was lost.  In figure 12B, splenocytes obtained from BCG-vaccinated animals were 
cultured for 4 days in the presence of 12.5µg/ml and 125µg/ml of rgpCCL5.  No 
statistically significant effect on splenocyte proliferation was observed.  
The effect of rgpCCL5 on splenocyte proliferation to PPD was evaluated from 
cells taken from BCG-vaccinated guinea pigs (Fig. 13).  RgpCCL5 (1250ng/ml) 
enhanced proliferative activity slightly at day 4, but was not different from media alone 
at days 1-3.  Blocking gpCCL5 function by co-cultures with anti-rgpCCL5 did not 
appear to affect splenocyte proliferative activity during the time intervals examined. 
 
DISCUSSION 
During M. tuberculosis infection, the development of a protective immune 
response likely requires the migration of proper leukocyte populations, the development 
of Th1 response, and the ability of macrophages to be activated to produce anti-
mycobacterial compounds (reactive oxygen and nitrogen intermediates).  Recent studies 
have suggested that chemokines are involved in many of these host immune responses 
(54, 142, 174).  Here we examined the contribution of gpCCL5 to these non-chemotactic 
functions during M. tuberculosis infections in the guinea pig. 
 We demonstrated that rgpCCL5 slightly enhanced H2O2 production within 
macrophages infected with M. tuberculosis (Fig. 9).  Previous studies have reported ROS 
production in response to CCL5 in eosinophils (36, 79, 91) but, to our knowledge, there 
is an absence of data supporting a direct link between CCL5 stimulation and macrophage 
ROS production.  However, recent reports of enhanced M. tuberculosis viability in  
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Figure 13:  The effect of rgpCCL5 on T lymphocyte proliferation to PPD.  Splenocytes 
were obtained from BCG-vaccinated guinea pigs and stimulated with rgpCCL5 
(1250ng/ml) or anti-rgpCCL5 IgG (1:100) and co-cultured with or without PPD 
(25ug/ml) for 1-4 days.  [3H] thymidine at 1µCi/well was added to each well 24 h (days 
1-3) or 6 h (day 4) before incubation time.  Cells were harvested and proliferative 
activity determined by counts per minute.  Results are representative of the mean + SEM 
from two independent experiments with triplicates performed with each treatment group.
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Human alveolar macrophages in the presence of anti-human CCL5 (174) suggest that 
CCL5 induces anti-mycobacterial products (i.e. ROS) in these cells.  We were 
disappointed, therefore, to observe that gpCCL5 did not appear to affect M. tuberculosis 
viability in guinea pig resident alveolar macrophages, and only minimally affected 
mycobacterial viability in resident peritoneal macrophages (Fig. 10).  These preliminary 
studies need to be repeated at different MOIs to verify these observations.  The data 
suggest that CCL5 might stimulate ROIs in eosinophils through different host receptors 
compared to macrophages.  Another plausible explanation is that eosinophil CCRs 
interact with other receptors within their lipid rafts, thus resulting in varying 
transmembrane signaling compared to macrophages.   
In Fig. 11, macrophages obtained from BCG-vaccinated guinea pigs displayed an 
enhanced ability to limit M. tuberculosis growth compared to macrophages isolated from 
naive guinea pigs.  A previous study indicated that alveolar macrophages isolated from 
BCG-vaccinated guinea pigs produce more H2O2 than naive macrophages when infected 
with H37Ra (84), suggesting a mechanism of how alveolar macrophages from BCG-
vaccinated guinea pigs can limit the growth of M. tuberculosis in vitro.   
 The ability of naive splenic lymphocytes to proliferate when stimulated with 
rgpCCL5 was evaluated.  We found that rgpCCL5 enhanced splenocyte proliferation 
minimally at 1250ng/ml, 12.5µg/ml, and 125µg/ml in splenocytes isolated from naive 
and/or BCG-vaccinated guinea pigs alone (Fig. 12).  Preliminary studies examining the 
effect of rgpCCL5 on antigen-specific lymphocyte proliferation to PPD in cells from 
BCG-vaccinated animals revealed minimal differences following treatment with 
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rgpCCL5 or anti-rgpCCL5 (Fig. 13).  This is in contrast with previous studies supporting 
CCL5’s ability to act in a mitogen-like manner by inducing T lymphocyte proliferation 
(14, 121, 193).  However, the published studies were performed with freshly isolated 
human T cells and human T cell clones.  In our studies, we used whole splenocytes 
instead of purified T lymphocytes to assess the role of gpCCL5 on naive and PPD-
specific lymphocyte proliferation.  No previous studies to our knowledge have reported 
splenocyte proliferation induced by CCL5.  Future studies looking at proliferation of 
guinea pig nylon wool purified T lymphocyte in the presence of rgpCCL5 will be 
performed to further evaluate differences and similarities among species.  A previous 
study performed by Campbell, et al. demonstrated variability between human and guinea 
pig eosinophils.  There was an absence of chemotactic properties associated with 
rgpCCL5 or rhCCL5 to guinea pig eosinophils (27).  This is in contrast with human 
studies, which have shown rhCCL5 to be chemotactic to eosinophils (4).  In these 
studies, there was a diminished ability of rgpCCL5 to induce splenocyte proliferation.  
Previous studies have exhibited human and murine CCL5’s ability to induce T 
lymphocytes proliferation (14, 121, 193).  This suggest the possibility of variability and 
selective differences between chemokines and/or leukocytes between guinea pigs and 
humans but, since we did not examine purified T lymphocytes in this study, further 
experiments need to be performed before these conclusions are accepted.         
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CHAPTER IV 
VACCINATION ENHANCES IL-12p40 mRNA LEVELS IN GUINEA PIG 
ALVEOLAR MACROPHAGES INFECTED WITH Mycobacterium tuberculosis 
 
INTRODUCTION 
 Mycobacterium tuberculosis continues to be one of the top three infectious killers 
in the world and claims two million lives a year.  The immune response plays a critical 
role in the development of the disease, specifically granuloma formation.  The 
granuloma is formed by a collection of cells, including macrophages and T lymphocytes, 
aggregating around the foci of infection.  The formation of a protective granuloma is 
partially dependent on the concentration and timing of chemokines and cytokines.  These 
proteins are responsible for attracting and activating leukocytes at the site of infection.  
IL-12 has long been known to be a crucial Th1 cytokine secreted by macrophages and 
responsible for differentiating CD4+ T lymphocytes into the Th1 phenotype.  These Th1 
effector cells release IFNγ, which results in macrophage activation and the production of 
elevated levels of anti-mycobacterial compounds, including reactive oxygen and 
nitrogen intermediates (23, 172).   
 More recently it has been shown that the IL-12p40 chain is involved in the 
composition of two Th1 cytokines, IL-12 and IL-23 (144).  These cytokines share a 
common receptor subunit, IL-12 Rβ1 (148), but interact with different T lymphocyte 
subpopulations.  IL-12 has been associated with the activation of naive T lymphocytes, 
whereas IL-23 is associated with the activation of memory T lymphocytes (103).  The 
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interaction of T cells with either IL-12 or IL-23 results in IFNγ production.  The IL-
12p40 subunit plays an important role during mycobacterial infections (39, 78) .  IL-
12p40 knockout mice infected with M. tuberculosis had higher bacterial burdens, 
abrogated delayed type hypersensitivity reactions, and a reduction in IFNγ production 
compared to wild type mice were observed (39, 78).  Together these data strongly 
support the necessity of the IL-12p40 subunit in eliciting a protective immune response 
to tuberculosis infection.   
      In this study, the expression of IL-12p40 mRNA levels was analyzed in guinea 
pig alveolar macrophages infected with virulent or attenuated strains of Mycobacterium 
tuberculosis, and the effect of BCG-vaccination on this response was documented.    
 
MATERIALS AND METHODS 
Animals and BCG vaccination.  Specific-pathogen-free, outbred, male and 
female Hartley guinea pigs from Charles River Breeding Laboratories, Inc. (Wilmington, 
MA) were housed in polycarbonate cages within an air-filtered environment under a 12 h 
light-dark cycle.  Food (Ralston Purina, St. Louis, MO) and tap water were supplied to 
the animals ad libitum.  Vaccination of guinea pigs was performed via intradermal 
injection of 0.1ml (103 CFU) of viable Mycobacterium bovis BCG (Danish 1331 strain, 
Statens Seruminstitut, Copenhagen, DK) into the left inguinal region.  All procedures 
were reviewed and approved by the Texas A&M University Laboratory Animal Care 
Committee.   
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Necropsy and alveolar macrophage isolation.  Four weeks after vaccination, 
guinea pigs were euthanized by two 1.5 ml intramuscular injections of sodium 
pentobarbital (100mg/ml) (Sleepaway Euthanasia Solution; Fort Dodge Laboratories, 
Inc., Fort Dodge, IA).  Bronchoalveolar lavage cells were obtained by placing an 18-
gauge cannula fixed to a 20ml syringe intra-tracheally.  Bronchoalveolar lavage was 
performed with 50ml of PBS containing 3% fetal bovine serum (FBS) and 12mM 
lidocaine.  These cells were washed with PBS and resuspended in RPMI 1640 with 
10µM 2-mercaptoethanol, 2µM L-glutamine, and 10% FBS (C-RPMI).  Alveolar 
macrophages (AM) were isolated by adherence to a 96-well plastic culture plate during 
1-2 hours of incubation at 37°C in a 5% CO2 in air atmosphere.  The cell cultures were 
washed twice with warm RPMI to remove nonadherent cells.  C-RPMI 1640 was added 
to the wells and the cells were rested for an additional 24 hours.    
Mycobacterium preparation.  Mycobacterium tuberculosis H37Rv (ATCC 
27294; American Type Culture Collection, Manassas, VA) and H37Ra (ATCC 25177) 
stored at –80°C were rapidly thawed, vortexed, and sonicated for 60s with an Ultrasonics 
sonicator (Heat Systems-Ultrasonics, Inc., Plainview, NY) at an output setting of 8.0 to 
remove clumps.   
 Cell cultures.  Alveolar macrophages were infected with H37Ra or H37Rv at a 
MOI 1:5 in C-RPMI with no antibiotics for 2 h.  Extracellular mycobacteria were 
removed by aspirating the media and washing the cells once.  Fresh C-RPMI was added 
to the wells and these samples were used as 0 h time point.  At each time interval, media 
was aspirated and cells were lysed with buffer RLT (Qiagen) and frozen at –80°C. 
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RNA isolation and real-time PCR.  RNA was isolated using QIAshredder 
followed by the RNeasy kit from Qiagen.  Reverse transcription was performed using 
Taqman reverse transcription reagents (Applied Biosystems).  Primer Express software 
(Applied Biosystems) was used to design the sequences for guinea pig 18S (forward 
primer, 5’-TGCATGGCCGTTCTTAGTTG – 3’; reverse primer, 5’-
AGTTAGCATGCCAGAGTCTCGTT – 3’) and IL-12p40 (forward primer, 5’-
GTGGTAGAGTTGGATTGGCACA – 3’; reverse primer, 5’-
TCCTCAGCAGTGTTGCAGGT – 3’).  Real time PCR was performed using SYBR 
Green PCR Supermix and the ABI Prism 7700 Sequence Detector from Applied 
Biosystem.  Fold induction levels of mRNA were obtained by analyzing cycle threshold 
(Ct) levels normalized to 18S Ct values and further normalized against values at 0 h.     
 Statistical analysis.  The differences between groups were analyzed for 
statistical significance using the Student’s t test with a two-tailed distribution.  The 
probability levels were set at 95%. 
 
RESULTS 
The effect of BCG-vaccination on M. tuberculosis infected alveolar 
macrophage expression of IL-12p40.  Figure 14 illustrates the effect of BCG-
vaccination on IL-12p40 mRNA expression in alveolar macrophages infected with M. 
tuberculosis.  In Fig. 14A, alveolar macrophages from naive and BCG-vaccinated guinea  
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Figure 14:  Alveolar macrophages exhibit enhanced IL-12p40 mRNA levels from BCG- 
vaccinated compared to naïve guinea pigs.  Rested AM were infected with attenuated 
H37Ra (A) and virulent H37Rv (B) M. tuberculosis (MOI 1:5) for 6, 12, 28, 24, 36, and 
48 h.  Differences in IL-12p40 mRNA were analyzed in M. tuberculosis infected 
macrophages obtained from naive (black bars) or BCG-vaccinated (white bars) animals.  
At each time interval, RNA was isolated from cells and reverse transcribed into cDNA.  
Real time analysis of the cDNA was performed in duplicates, and IL-12p40 mRNA fold 
inductions were determined by normalizing IL-12p40 threshold cycle (Ct) values against 
18S values.  This was further normalized against mRNA from infected macrophages at 0 
h.  The bars above represent the mean ± SEM of three animals.  Statistical analysis was 
done analyzing H37Ra versus H37Rv at each time point and values of p < 0.05 (*) were 
considered significant.
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Pigs were isolated and infected with an attenuated strain of M. tuberculosis (H37Ra) at a 
MOI 1:5 for 6, 12, 18, 24, 36, and 48 h.  At each time interval RNA was isolated, reverse 
transcribed into cDNA, and analyzed by real-time PCR.  As early as 6 h, elevated levels 
of IL-12p40 mRNA appeared in macrophages obtained from BCG-vaccinated compared 
to naive animals.  Significant (p < 0.05) differences between the treatment groups were 
apparent at 12 h with about 2-fold higher expression levels in macrophages obtained 
from BCG-vaccinated guinea pigs.  The mRNA fold induction levels, though not 
statistically significant, remained slightly elevated in macrophages obtained from BCG-
vaccinated animals compared to naive throughout the course of the experiment.  In fig. 
14B, live virulent M. tuberculosis (H37Rv) was used to infect alveolar macrophages.  
This resulted in significant (p < 0.05) enhancement of IL-12p40 mRNA in macrophages 
obtained from BCG-vaccinated animals as early as 6 h.  A three-fold difference between 
the groups was observed at 12 h, however, at 18 h the expression level of IL-12p40 
mRNA in macrophages from vaccinated animals declined to levels similar to naive 
macrophages.   
Differences between IL-12p40 mRNA expression in alveolar macrophages 
infected with an attenuated versus virulent strain of M. tuberculosis.  Figure 15 
illustrates the variation in IL-12p40 mRNA expression between alveolar macrophages 
infected with an attenuated (H37Ra) or a virulent (H37Rv) strain of M. tuberculosis.  In 
figure 15A, alveolar macrophages were obtained from naive guinea pigs and infected for 
6, 12, 18, 24, 36, and 48 h with either M. tuberculosis H37Ra or H37Rv at a MOI 1:5.  
IL-12p40 mRNA expression was determined by real-time PCR analysis.  Although not  
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Figure 15:  Virulent M. tuberculosis H37Rv induces a more rapid upregulation of IL-
12p40 mRNA than an attenuated (H37Ra) strain.  AM were isolated from naive (A) and 
BCG-vaccinated (B) guinea pigs and infected with attenuated H37Ra (black bars) or 
virulent H37Rv (white bars) strains of M. tuberculosis (MOI 1:5) for 6, 12, 28, 24, 36, 
and 48 h.  At each time interval, RNA was isolated from cells and reverse transcribed 
into cDNA.  Real time analysis of the cDNA was performed in duplicates, and IL-12p40 
mRNA fold inductions were determined by normalizing IL-12p40 threshold cycle (Ct) 
values against 18S values.  This was further normalized against mRNA from infected 
macrophages at 0 h.  Statistical analysis was done analyzing H37Ra versus H37Rv at 
each time point.  The bars above represent the mean ± SEM of three animals.  Values of 
p < 0.05 (*) were considered significant.     
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Statistically significant, H37Rv induced IL-12p40 mRNA to a greater extent early (6 and 
12 h) during the infection, while H37Ra induced higher levels throughout the rest of the  
experiment.  In figure 15B, alveolar macrophages were isolated from BCG-vaccinated 
guinea pigs and infected with either H37Ra or H37Rv.  A similar kinetic pattern was 
observed in macrophages obtained from naive and vaccinated animals, however, H37Rv 
induced significantly (p < 0.05) elevated IL-12p40 mRNA compared to H37Ra at 12 h 
post-infection.  As the infection proceeded, this pattern was reversed and at 24 and 36 h 
H37Ra induced IL-12p40 mRNA levels which were significantly (p < 0.05) higher than 
those induced by H37Rv.   
    
DISCUSSION 
The current tuberculosis vaccine, BCG, though varying in efficacy, provides a 
degree of protection especially against the dissemination of M. tuberculosis (65).  The 
development of a more protective vaccine would be facilitated by an understanding of 
the mechanisms of protection elicited by BCG.  Considering the multitude of similarities 
shared between the pathogenesis of tuberculosis in guinea pigs and humans (127), 
guinea pigs provide a useful model to test new vaccines against tuberculosis.  BCG 
vaccination induces significant protection against disseminated disease in the guinea pig 
(129), thus it is important to dissect the protective immune response elicited in BCG-
vaccinated compared to naive guinea pigs (7, 106, 118).   
In these studies, we elucidated the effect of BCG-vaccination on IL-12p40 
mRNA expression in alveolar macrophages obtained from guinea pigs.  We 
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demonstrated a significantly enhanced expression of IL-12p40 mRNA in macrophages 
isolated from BCG-vaccinated guinea pigs, suggesting the importance of this cytokine 
subunit in eliciting a protective immune response against M. tuberculosis.  These 
findings further support previous results demonstrating the importance of IL-12 and IL-
23 in providing protection against M. tuberculosis in mice (39, 78, 96) and humans (2, 
69, 197).  Due to lack of available guinea pigs reagents, studies focusing on IL-12 and 
IL-23 protein production could not be carried out.  The story is incomplete without these 
data.  However, our IL-12p40 mRNA results strengthen the potential importance of 
these Th1 cytokines in providing protection against tuberculosis and display another 
similarity between humans and guinea pigs.  Previous studies in our lab have 
demonstrated enhanced CXCL8, CCL2, CCL5, IFNγ, TNFα, and IL-1β mRNA and/or 
protein in M. tuberculosis-infected leukocytes from BCG-vaccinated guinea pigs in vitro 
compared to cells from naive animals (85, 86, 106, 118).  These findings aid in the 
understanding of which cytokines/chemokines are involved in eliciting a protective 
immune response against tuberculosis.   
 Previous studies in our lab have demonstrated differences in the induction of 
inflammatory cytokines and chemokines between virulent (H37Rv) and attenuated 
(H37Ra) strains of M. tuberculosis (106, 118), suggesting bacterial virulence is related to 
the macrophage response.  In these studies, macrophages obtained from naive guinea 
pigs had similar IL-12p40 mRNA levels when infected with H37Ra or H37Rv.  
However, alveolar macrophages isolated from BCG-vaccinated guinea pigs displayed a 
significant difference in IL-12p40 mRNA expression after infection with attenuated 
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versus virulent strains of M. tuberculosis.  H37Rv induced a rapid upregulation of IL-
12p40 mRNA as early as 6 h with significant enhancement over H37Ra by 12 h.  This 
elevated response was transient and by 24 h IL-12p40 expression levels declined over 30 
fold.  In contrast, levels of IL-12p40 mRNA in H37Ra infected macrophages dropped 
slightly over 3 fold between 12 h to 48 h.  This suggests that virulent M. tuberculosis 
might down-modulate the production of IL-12/IL-23, leading to an attenuation of the 
host immune response, thus, ensuring its own persistence.  Previous studies in our lab 
have demonstrated the ability of virulent M. tuberculosis to induce significantly lower 
CXCL8 mRNA levels in alveolar macrophages than the attenuated strain (118) .  
However, in that study, CXCL8 protein levels were not affected.  Therefore, it is 
important that we measure IL-12/IL-23 protein levels before drawing any definitive 
conclusions.  It is also possible that an increase in bacterial uptake by the macrophage 
occurs with virulent compared to attenuated M. tuberculosis.  This may result in more 
immediate expression of IL-12p40 mRNA.  However, the kinetic patterns of IL-12p40 
mRNA between the two strains is particularly interesting because infections with H37Rv 
results in rapid decline in IL-12p40 mRNA levels after 12 h (Fig. 15B).  These findings 
may be due to a reduction in macrophage viability, however, this effect was not 
examined in the present study.  Unpublished studies in our lab have demonstrated 
unaltered macrophage viability in cells infected with M. tuberculosis at MOIs of 1:5 or 
less, suggesting that the aforementioned explanation is unlikely.  In contrast, at 24 and 
36 h, attenuated M. tuberculosis induced significantly higher levels of IL-12p40 mRNA 
compared to the virulent strain (Fig. 15B).  This rapid decline in IL-12p40 mRNA in 
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virulent M. tuberculosis-infected alveolar macrophages could be associated with a 
survival mechanisms developed by the bacteria.  However, protein data for IL-12 and 
IL-23, as well as a correlation with bacterial viability, need to be obtained before these 
conclusions can be drawn.    
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CHAPTER V 
 
EFFECT OF BCG VACCINATION ON CCL5 PRODUCTION IN VITRO AND IN 
 
VIVO IN RESPONSE TO Mycobacterium tuberculosis IN THE GUINEA PIG 
 
 
 
INTRODUCTION 
Millennia have passed and still tuberculosis (TB) persists in our world, infecting 
one third of the world’s population and claiming ~ 2 million lives per year (56).  We are 
in great need of a new vaccine against tuberculosis due to the varying efficacy (0-80%) 
of the current BCG vaccine (38, 162).   The development of a better tuberculosis vaccine 
has been the focus of concerted studies throughout the world, including protection trials 
in numerous animal models, such as mice, rabbits, guinea pigs, and monkeys (128, 132).  
Guinea pigs display protection following vaccination with BCG, disease progression 
similar to that of humans and potent delayed-type hypersensitivity, following infection 
with a low aerosol dose of M. tuberculosis.  Therefore, guinea pigs are considered to be 
an excellent animal model in which to study novel TB vaccines (145). 
     To better design a more efficacious vaccine against TB, we need to further develop 
our understanding of the guinea pig immune response elicited by BCG vaccination in 
response to M. tuberculosis infection.  A pivotal step in the containment of infection is 
the formation of a protective granuloma, which is dependent on many components of the  
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Host immune response, including numerous cytokines and chemokines.  Abnormal 
granuloma formation has been observed in the absence of TNFα (24, 161), IL-12 (78), 
and IFNγ (34, 190).  Chemokines have also been suggested to play a crucial role in 
granuloma formation (5, 34, 35, 68, 158, 161), due to their chemotactic properties for 
macrophages/monocytes and T lymphocytes.  Of particular interest is the CC 
chemokine, CCL5 (RANTES), because of its ability to attract T lymphocytes and 
macrophages, which are involved in protection against M. tuberculosis (14, 142, 175, 
209), to induce a Th1 response (54, 125, 217), to activate and expand populations of T 
lymphocytes (11, 14, 54, 193, 209), and to augment the delayed type hypersensitivity 
response (34, 35, 48, 121).  Recently, CCL5 has been shown to play a role in 
diminishing M. tuberculosis viability in macrophages (174).  Previous studies have 
shown elevated levels of CCL5 in the bronchoalveolar lavage fluid from individuals 
with human pulmonary tuberculosis (81, 101, 167) and reduced levels in those co-
infected with immunosuppressive diseases, like HIV/AIDS, suggesting an important role 
of this chemokine in providing protection against tuberculosis.  Human monocytes 
(167), monocyte-derived dendritic cells (206), and alveolar macrophages (167, 174) 
have been shown to secrete CCL5 in response to M. tuberculosis infection. 
      Due to the lack of reagents for the guinea pig, much remains to be elucidated 
regarding the immune response against M. tuberculosis and the protective effect of BCG 
vaccine.  Previous work in our laboratory has revealed enhanced expression and 
production of TNFα (106) and CXCL8 (IL-8) (118) from different cell populations 
isolated from BCG-vaccinated guinea pigs compared to non-immunized animals.  We 
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have also observed heightened mRNA levels of IL-1β (85) and CCL5 (85) in M. 
tuberculosis-infected macrophages isolated from BCG-vaccinated guinea pigs.  In these 
studies, the effect of BCG vaccination on CCL5 mRNA expression and protein 
production from different guinea pig leukocyte populations infected with M. tuberculosis 
in vitro was elucidated.  This is the first time gpCCL5 protein has been detected and 
quantified in the guinea pig.  BCG vaccination enhanced the levels of CCL5 mRNA and 
secreted protein from macrophages and splenocytes infected with M. tuberculosis 
(H37Rv).  The well-established guinea pig model of tuberculosis pleurisy (154) was 
used to quantify levels of CCL5 in vivo.  High concentrations of CCL5 mRNA and 
protein were observed in pleural exudate cells and fluid aspirated from the pleural 
cavity.   
 
MATERIALS AND METHODS 
Mycobacterium preparation.  Mycobacterium tuberculosis H37Rv (ATCC 
27294; American Type Culture Collection, Manassas, VA) stored at –80°C was rapidly 
thawed, vortexed, and sonicated for 60s with an Ultrasonics sonicator (Heat Systems-
Ultrasonics, Inc., Plainview, NY) at an output setting of 8.0 to remove clumps.   
Production of polyclonal anti-guinea pig CCL5.  Recombinant guinea pig 
CCL5 was obtained as previously described (184).  Rabbits were injected three times 
with rgpCCL5 (0.1mg) with TiterMax Gold adjuvant (Sigma, St. Louis, MO) at three 
week intervals.  Blood was collected by exsanguination and centrifuged at 200 × g for 30 
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minutes to obtain total serum.  The specificity of the anti-serum was detected against 
recombinant guinea pig (rgp) CCL5 using Western blot analysis.   
SDS-PAGE analysis and Western blot.  Recombinant gpCCL5 was analyzed 
by SDS-PAGE using 10-20% tris-tricine gels (Invitrogen, Carlsbad, CA).  The protein 
was transferred to polyvinylidene difluoride (PVDF) membranes (Invitrogen, Carlsbad, 
CA) using 350 mAmps from a Power Pac 300 (Bio-rad, Hercules, CA).  The membrane 
was than washed to eliminate any transfer buffer.  Western blot was performed using 
rabbit anti-rgpCCL5 serum and the Western Breeze Chromogenic Immunodetection Kit 
(Invitrogen, Carlsbad, CA) following the user manual.   
Animals and vaccination.  Outbred male and female Hartley guinea pigs from 
Charles River Breeding Laboratories, Inc. (Wilmington, MA) were housed in 
polycarbonate cages within an air-filtered environment under a 12 h light-dark cycle.  
Food (Ralston Purina, St. Louis, MO) and tap water were supplied to the animals ad 
libitum.  Vaccination of guinea pigs was performed via intradermal injection of 0.1ml 
(103 CFU) of viable Mycobacterium bovis BCG (Danish 1331 strain, Statens 
Seruminstitut, Copenhagen, DK) into the left inguinal region.  All procedures were 
reviewed and approved by the Texas A&M University Laboratory Animal Care 
Committee.   
Necropsy and macrophage isolation.  Guinea pigs were euthanized by two 1.5 
ml intramuscular injections of sodium pentobarbital (100mg/ml) (Sleepaway Euthanasia 
Solution; Fort Dodge Laboratories, Inc., Fort Dodge, IA).  The abdominal and thoracic 
cavities were opened aseptically and resident peritoneal macrophages were obtained by 
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flushing the peritoneal cavity twice with 30ml of cold phosphate-buffered saline (PBS) 
with 10U/ml heparin and 2% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, 
GA).  Alveolar macrophages were obtained by exposing the trachea and inserting an 18-
gauge cannula fixed to a 20 ml syringe.  The bronchoalveolar lavage (BAL) was 
performed by filling the lungs with cold 12mM lidocaine in PBS containing 3% FBS as 
previously described (118).  Cells were pelleted by centrifuging at 320 × g for 15 
minutes at 4°C.  These pellets were washed twice with cold PBS.  The cells were 
resuspended in 1ml of Macrophage-SFM (Invitrogen, Carlsbad, CA), and viable cells 
were enumerated on a hemacytometer by Trypan blue exclusion (Gibco Life 
Technologies, Grand Island, NY).  Cells from BAL and peritoneal cavity were 
resuspended at 1×106 cells/ml and 500µl/well were added to a 48-well polystyrene plate.  
Preparation of splenocytes.  Spleens were removed aseptically from the 
peritoneal cavity after resident peritoneal cells were harvested and placed in RPMI-1640 
medium (Irvine Scientific, Santa Anna, CA) with 10µM 2-mercaptoethanol, 2 µM L-
glutamine, and 10% heat-inactivated FBS.  Spleens were homogenized and erythrocytes 
were lysed with ACK lysis buffer (0.14M NH4Cl, 1.0mM KHCO3, 0.1mM Na2EDTA 
[pH 7.2 – 7.4]).  Splenocytes were washed twice in RPMI medium without fetal bovine 
serum, and resuspended in Macrophage-SFM at a concentration of 1 × 106 cells/ml 
determined by excluding dead cells using Trypan blue exclusion and enumerating 
splenocytes on a hemacytometer.  Splenocytes were added to a 24-well polystyrene plate 
in a volume of 1ml/well.       
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Cell stimulation.  Alveolar and peritoneal macrophages were isolated via 
adherence to polystyrene plates for 1.5 – 2 h at 37°C.  Nonadherent cells were removed 
by washing wells with warm Macrophage – SFM media.  Purified macrophages were 
infected with M. tuberculosis H37Rv at a multiplicity of infection (MOI) of 1:5 for 2 h at 
37°C.  Extracellular bacteria were aspirated and fresh Macrophage-SFM was added to 
each well (time = 0h).  Splenocytes were infected with M. tuberculosis H37Rv at MOI 
1:5.  At the appropriate time points, supernatants were aspirated, centrifuged at 8,000 × g 
for 5 minutes, and stored at –80°C until analyzed for CCL5 by ELISA.   
Tuberculous pleurisy experiment.   M.  tuberculosis H37Rv was heat-killed by 
exposure to 80°C water bath for 2 h and resuspended at 5.5 × 107 CFU/ml in sterile, 
endotoxin-free 0.9% sodium chloride solution (Sigma, St. Louis, MO).  Pleurisy was 
induced 5 wks post-BCG-vaccination by the administration of 1 ml of heat-killed M. 
tuberculosis H37Rv bilaterally into the pleural cavity (day 0) of anesthetized vaccinated 
guinea pigs.  Anesthesia was performed following a previous protocol (154).  At daily 
intervals post-pleurisy induction, guinea pigs were euthanized and fluid in the pleural 
cavity was aspirated and centrifuged at 200 × g for 15 min to remove inflammatory cells.  
The fluid was transferred to a new tube and centrifuged at 1400 × g for 20 min and 
supernatants were stored at –80°C until tested for CCL5 protein by ELISA.            
Total RNA isolation and real-time PCR.  Total RNA was isolated from 
adherent and nonadherent cell populations using the RNeasy kit (QIAGEN, Valencia, 
CA) with the addition of Rnase-free DNase according to the manufacturer’s instructions.  
Reverse transcription was performed on 1-5µg of total RNA using TaqMan Reverse 
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Transcription Reagents (Applied Biosystems, Foster City, CA).  Negative controls were 
included to ensure PCR amplification of cDNA was not due to contaminating genomic 
DNA.  Real-time PCR analysis was performed on the cDNA using SYBR Green I 
(Applied Biosystems) following a previously published protocol (118).  Primer Express 
software (Applied Biosystems) was used to design the sequences for guinea pig 
hypoxanthine phosphoribosyltransferase (HPRT) (forward primer, 
AGGTGTTTATCCCTCATGGACTAATT; reverse primer, 
CCTCCCATCTCCTTCATCACAT) and guinea pig CCL5 (forward primer, 
CTGGCCCACTGCTTAGCAAT; reverse primer, CCTTGCTTCTTTGCCTTGAAA).  
Real-time PCR was performed using the Applied Biosystems 7500 Real-Time PCR 
System following the manufacturer’s instructions.  Results were expressed as fold 
induction of mRNA, which was determined by normalizing CCL5 threshhold cycle (Ct) 
values against HPRT values.  This was further normalized against pooled mRNA of cells 
obtained from non-vaccinated animals and infected with M. tuberculosis at time zero.  
For pleurisy studies, CCL5 was normalized against HPRT values, and further 
normalized against Ct values from pleural cells derived from BCG-vaccinated, pleuritis-
free (not antigen-injected) animals. 
Enzyme-linked immunosorbent assay (ELISA) for guinea pig CCL5 protein.  
Diluted rabbit polyclonal anti-recombinant guinea pig (rgp)CCL5 in PBS + 0.05% 
Tween 20 (Sigma, St. Louis, MO) with 1% bovine albumin fraction V (Gemini, 
Woodland, CA) was added to Reacti-BindTM Protein A coated plates (Pierce, Rockford, 
IL) and incubated overnight at 4°C.  The following day the antibody solution was 
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washed four times with PBS + 0.05% Tween 20 (PBST).  Recombinant gpCCL5 
standards (40 – 1280 pg/ml) and supernatants from cell cultures were diluted in 
Macrophage-SFM and incubated for 3 h at 37°C.  The wells were washed and then 
incubated with 375 pg/ml of biotinylated (EZ-LinkTM Sulfo-NHS-LC-Biotin; Pierce, 
Rockford, IL) rgpCCL5 for one hour at 37°C.  Wells were washed and detection of 
biotinylated CCL5 was performed by incubating with peroxidase-conjugated 
streptavidin (150µl/well of 833pg/ml) (Jackson ImmunoResearch Laboratories, Inc., 
West Grove, PA) for 1 h at 37°C.  Plates were washed with PBST with a final wash of 
0.1 M sodium acetate (pH 5.5).  Colormetric analysis was determined by adding 
substrate 3, 3’, 5, 5’ – tetramethylbenzidine (TMB) (150µl/well) (BD Biosciences 
Pharmingen, San Diego, CA) and incubating in a dark environment for 15 minutes.  
Color development was stopped with the addition of 10% sulfuric acid, and plates were 
read on a Dynatech MR5000 automated plate reader (Dyantech Laboratories, Inc., 
Chantilly, VA) at 450nm.  Sample concentrations were derived from the rgpCCL5 
standard curve.   
Statistical analysis.  Analysis of variance was used to determine the significance 
of main treatment effects (vaccination status) and differences between time intervals 
within treatment groups.  Mean differences between rgpCCL5 mRNA and protein 
isolated from BCG vaccinated and naive guinea pigs were tested at a 95% confidence 
interval using the Duncan post hoc analysis.  The statistical tests were performed using 
SAS software (release 8.01; SAS Institute, Inc., Cary, NC).   
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RESULTS 
Development of a gpCCL5 ELISA.  We designed an ELISA that could detect 
gpCCL5 with high sensitivity considering the low physiological levels of CCL5 (pg-
ng/ml) previously detected in other animal models (167, 182).  The development of an  
ELISA involved the production of rgpCCL5, which was previously described (184), and 
polyclonal anti-rgpCCL5.  Figure 16A illustrates rgpCCL5 cloned into pET30Xa/LIC 
vector and induced by 0.1mM IPTG (Fig. 16A, lane 4; uninduced, lane 3).  Purified 
rgpCCL5 was obtained using reverse phase HPLC before and after cleavage with 
endopeptidase, Factor Xa (Fig. 16A, lane 5).  Recombinant human CCL5 was used as a 
control (Fig. 16A, lane 7).  In Figure 16B, the specificity of anti-serum (1:1000 dilution) 
from a rabbit immunized against gpCCL5 is displayed.  It is apparent that the anti-serum 
binds to mature rgpCCL5 (Fig. 16B, lane 1-3).   
Figure 17 illustrates the standard curve for the ELISA assay using a range of 
two-fold dilutions of rgpCCL5 and the rabbit anti-guinea pig CCL5 serum discussed 
above.  The anti-rgpCCL5 antiserum was bound to a protein A-coated plate.  Then 
biotinylated rgpCCL5 and unlabeled rgpCCL5 were allowed to compete for binding to 
the Fab portion of IgG on the plate as described in Materials and Methods.  This 
standard curve was used to quantitate gpCCL5 levels in samples.  The absence of 
unlabeled rgpCCL5 (0 pg/ml) resulted in a response greater than two standard deviations 
below the lowest concentration of rgpCCL5 used on the standard curve (40pg/ml) (data 
not shown).              
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Figure 16:  Specificity of rabbit anti-rgpCCL5 serum was tested by Western blot.  In 
Panel A, a SDS-PAGE analysis was performed on the expression and purification of 
rgpCCL5 and compared to rhCCL5.  The mature sequence of gpCCL5 was subcloned 
into pET30 Xa/LIC and was expressed using 0.1mM IPTG and further purified using 
reverse phase HPLC.  The mature protein was achieved by a blunt cleavage of the 5’ tag 
using Factor Xa leaving only the mature sequence.  The mature product was further 
purified using reverse phase HPLC.  Lane 1, low molecular weight ladder, lane 2, empty, 
lane 3, uninduced total E. coli protein, lane 4, cellular proteins from 0.1mM IPTG 
induction, lane 5, purified mature rgpCCL5, lane 6, empty, and lane 7, rhCCL5.  In 
Panel B, purified rgpCCL5 was then used to immunize rabbits, and anti-serum (1:1000 
dilution) was taken three months later.  A Western blot was used to detect rgpCCL5 
specificity.  Lane 1-3, rgpCCL5 at two-fold dilutions.
7
16
B
kDa
1             2            3
A
1      2    3  4      5   6       7
7
16
17
105
78
55
45
34
4
 76
 
 
Figure 17:  Standard curve for the guinea pig CCL5 ELISA.  Protein A coated plates 
were incubated with rabbit anti-guinea pig CCL5 (same anti-serum as that tested in the 
western blot in figure one).  Unlabelled recombinant CCL5 was used at two-fold 
dilutions to develop a standard curve.  Biotinylated rgpCCL5 was then added to compete 
with unlabeled CCL5.  Horseradish peroxidase was added followed by TMB substrate 
for 15’ in the dark.  The data points on the curve represent the average of quadruplicate 
wells + SEM.  The equation for the standard curve is depicted above with the R2 value, 
which exceeds 0.99.  The range of the standard curve is 40-1250pg/ml of CCL5 with 
0pg/ml being two standard deviations lower than the 40pg/ml (data not shown).  
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Effects of BCG vaccination on gpCCL5 mRNA and protein production in 
resident alveolar macrophages infected with M. tuberculosis.  Alveolar macrophages 
from naive and BCG-vaccinated guinea pigs were obtained as indicated above and 
infected with live virulent M. tuberculosis H37Rv (MOI 1:5) for 6, 12, 24, 48, and 72 h.  
At each time point, supernatants were collected and analyzed for gpCCL5 protein, and 
mRNA was isolated and analyzed using real-time PCR from cDNA obtained by reverse 
transcription.  Figure 18 shows the difference in CCL5 mRNA and production by M. 
tuberculosis- infected alveolar macrophages obtained from BCG-vaccinated and naive 
guinea pigs.  In Figure 18A, it is evident that infection of alveolar macrophages with 
virulent M. tuberculosis H37Rv stimulated the expression of CCL5 mRNA.  This 
expression is seen immediately following 2 h infection of macrophages from BCG-
vaccinated guinea pigs (t = 0 h) and peaks around 24 h.  Alveolar macrophages obtained 
from naive guinea pigs had a delayed CCL5 mRNA response to M. tuberculosis with 
peak expression occurring at 48 h post-infection.  Significance was not observed 
between treatment groups due to the high degree of variability.  In Figure 18B, secretion 
of CCL5 protein was observed at levels ~ 100-200pg/ml as early as 12 h post-infection 
from both naive and BCG-vaccinated guinea pigs.  Supernatants of alveolar 
macrophages obtained from BCG-vaccinated animals contained significantly higher 
levels (p < 0.05) of CCL5 protein at 72 h.  It was also apparent that at 72 h post-
infection, alveolar macrophages obtained from BCG-vaccinated guinea pigs secreted 
significantly elevated levels (p < 0.05) of CCL5 compared to all other time intervals 
observed within the same treatment group.  In contrast, macrophages obtained from 
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Figure 18:  CCL5 mRNA and protein production is enhanced in alveolar macrophages 
isolated from BCG-vaccinated compared to naive guinea pigs.  Alveolar macrophages 
from naive (white bars) and BCG-vaccinated (black bars) animals were isolated and 
infected with M. tuberculosis H37Rv (MOI 1:5) for 0, 6, 12, 24, 48, and 72 h.  At each 
time point, total RNA was isolated from the macrophages and supernatants were 
aspirated and analyzed by ELISA.  Panel A:  Results were expressed as fold induction of 
mRNA, which was determined by normalizing CCL5 threshold cycle (Ct) values against 
HPRT values.  This was further normalized against pooled mRNA from naive cells 
infected with M. tuberculosis at zero hours.  Panel B:  Supernatants from infected 
macrophages were analyzed for guinea pig CCL5 using ELISA.  Data represent mean + 
SEM of 3-4 experiments.  An asterisk represents significance (p < 0.05) from all time 
points within a treatment group.  A double asterisk represents significance (p < 0.05) 
between alveolar macrophages from naive and BCG-vaccinated animals at similar time 
points.  ANOVA was used to analyze significance between groups.       
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Figure 18 continued.
0.00
100.00
200.00
300.00
400.00
500.00
600.00
12hr 24hr 48hr 72hr
gp
C
C
L5
 (p
g/
m
l)
Naive
BCG
***
B
 80
naive animals displayed no significant difference in CCL5 secretion over time in culture.   
Effects of BCG vaccination on CCL5 mRNA and protein production in 
resident peritoneal macrophages infected with M. tuberculosis.  Figure 19 illustrates 
the effects of BCG vaccination on CCL5 mRNA expression and protein secretion in 
resident peritoneal macrophages infected with virulent mycobacteria.  In Figure 19A, 
peritoneal macrophages obtained from BCG-vaccinated guinea pigs exhibited similar 
results to alveolar macrophages immediately after infection (t = 0 h, 2 h post-infection) 
with heightened CCL5 mRNA levels, though not significant.  There was no significant 
difference in CCL5 mRNA expression between uninfected macrophages from naive or 
BCG-vaccinated animals.  However, as early as 6 h post-infection, peritoneal 
macrophages obtained from BCG-vaccinated animals displayed significantly (p < 0.05) 
elevated levels of CCL5 mRNA compared to cells obtained from naive animals.  Levels 
of CCL5 mRNA steadily increased throughout the 48 h of infection in the BCG-
vaccinated peritoneal macrophages.  This contrasted with the relatively low levels of 
CCL5 mRNA observed in peritoneal macrophages obtained from naive animals 
throughout the infection.  Secreted CCL5 protein from M. tuberculosis H37Rv-infected 
peritoneal macrophages (Fig. 19B) correlated with patterns seen at the transcriptional 
level.  Infected macrophages obtained from naive guinea pigs never reached CCL5 
protein levels higher than 350pg/ml, while CCL5 was secreted at significantly higher 
levels in resident peritoneal macrophages obtained from BCG-vaccinated at 48 and 72 h.  
At these time intervals post-infection, secreted CCL5 was significantly elevated (p < 
0.05) compared to levels at 12 and 24h within the BCG-vaccinated group.      
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Figure 19:  BCG-vaccination affects CCL5 mRNA and protein levels in guinea pig 
resident peritoneal macrophages.  Resident peritoneal macrophages were isolated from 
naive (white bars) and BCG-vaccinated (black bars) guinea pigs and infected with M. 
tuberculosis H37Rv (MOI 1:5).  At different time points (0, 6, 12, 24, 48, and 72 h), 
supernatants were collected and RNA was isolated from infected macrophages.  The 
RNA was reverse transcribed into cDNA and real time PCR using SYBR Green was 
performed.  Panel A:  Results were expressed as fold induction of mRNA, which was 
determined by normalizing CCL5 threshold cycle (Ct) values against HPRT values.  This 
was further normalized against pooled mRNA from naive cells infected with M. 
tuberculosis at zero hours.  Panel B:  Supernatants from infected macrophages were 
analyzed for guinea pig CCL5 using ELISA.  Results are representative of the mean + 
SEM of 4-5 separate experiments.  Significant (p < 0.05) production of CCL5 protein 
from 12 and 24 h within treatment groups is denoted by an asterisk.  Significance (p < 
0.05) between naive and BCG-vaccinated at similar time points is depicted by a double 
asterisk.  Significance was determined using ANOVA.      
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Effects of BCG vaccination on CCL5 mRNA and protein production in 
splenocytes infected with M. tuberculosis.  Figure 20 illustrates the effect BCG-
vaccination on CCL5 mRNA expression and protein secretion in infected splenocytes.  
In Figure 20A, a significant difference (p < 0.05) was demonstrated between CCL5 
mRNA in uninfected splenocytes obtained directly from naive and BCG-vaccinated 
guinea pigs (time point = 0 h).  In contrast to infected macrophages, CCL5 mRNA was 
significantly enhanced (p < 0.05) in M. tuberculosis infected splenocytes from naive 
guinea pigs at 12 and 24 h compared with time zero.  Splenocytes from BCG-vaccinated 
animals exhibited a similar kinetic pattern with a significant enhancement (p < 0.05) of 
CCL5 mRNA at 24 h compared to zero hours.  Surprisingly, these fold induction levels 
in CCL5 mRNA were approximately half the values of infected macrophages.  It was 
also evident that CCL5 mRNA was significantly elevated (p < 0.05) at 24 h in M. 
tuberculosis-infected splenocytes obtained from BCG-vaccinated compared to naive 
guinea pigs.  In Figure 20B, the secretion of CCL5 protein from infected splenocytes 
displayed novel kinetics.  As early as 6 h post-infection, a measurable quantity of CCL5 
protein (~ 1000 pg/ml) was detected.  However, at this time point there was no 
difference between splenocytes obtained from BCG-vaccinated and naive guinea pigs.  
As the infection progressed, splenocytes from naive guinea pigs maintained the same 
levels of CCL5 protein as those observed at 6 h.  In contrast, splenocytes from 
vaccinated animals displayed CCL5 kinetics similar to resident macrophage populations 
reaching significantly enhanced levels of CCL5 at 24, 48, and 72 h compared to 6 h after 
infection (p < 0.05).  Additionally, significant differences between secreted CCL5 in  
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Figure 20:  Vaccination with BCG affects CCL5 mRNA expression and protein 
production from splenocytes infected with M. tuberculosis.  Splenocytes were obtained 
from naive (clear bars) and BCG-vaccinated (black bars) guinea pigs and infected with 
M. tuberculosis H37Rv (MOI 1:5) for various times (0, 6, 12, 24, 48, and 72 h).  At each 
time point, total RNA was collected, reverse transcribed into cDNA, and real time PCR 
using SYBR Green was performed.  Panel A: results were expressed as fold induction of 
mRNA, which was determined by normalizing CCL5 threshold cycle (Ct) values against 
HPRT values.  This was further normalized against pooled mRNA from naive cells 
infected with M. tuberculosis at zero hours.  Panel B: supernatants were collected from 
each sample and analyzed by ELISA to detect CCL5 protein levels.  .  Data represent 
mean + SEM of 3-4 experiments.  An asterisk represents significance (p < 0.05) between 
gpCCL5 values from the first time point displayed within treatment groups.  A double 
asterisk represents significance (p < 0.05) between splenocytes from naive and BCG-
vaccinated animals at similar time points.  ANOVA was used to analyze significance 
between groups.       
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splenocytes obtained from naive and vaccinated guinea pigs were apparent after 
infecting the cells for 24, 48, and 72 h with M. tuberculosis H37Rv (MOI 1:5).    
CCL5 mRNA expression and protein production during tuberculous 
pleurisy in the guinea pig.  A model of tuberculous pleurisy has been well established 
in the guinea pig model (7, 8) and provides a method to assess the development of a 
mycobacterial-specific inflammatory response in BCG-vaccinated guinea pigs.  A 
previous study showed peak levels of fluid accumulation in the pleural space at day 5 
following intrapleural injections of killed mycobacteria (8).  In Figure 21, pleural 
samples from days 1-5 were further analyzed for CCL5 mRNA expression in pleural 
exudate cells and secreted CCL5 protein in the pleural fluid.  As shown in Figure 21A, 
significant levels (p < 0.05) of CCL5 mRNA were seen at days 3 and 4, with peak 
induction levels on day 4 expressing 100-fold greater levels than resident pleural cells 
obtained from BCG-vaccinated pleuritis-free (i.e., not injected with heat-killed M. 
tuberculosis) animals.  Figure 21B demonstrates a similar trend with CCL5 protein in 
pleural fluid.  Secreted protein peaked at days 3 and 4, reaching concentrations ~ 50,000 
pg/ml.  These CCL5 protein levels were greater than 6 – fold from all in vitro M. 
tuberculosis-infected leukocytes.     
 
DISCUSSION 
In this paper, data are presented which advance our understanding of the 
protective role of vaccination with M. bovis BCG in a highly relevant guinea pig model.   
 87
 
 
Figure 21:  A kinetic study of CCL5 mRNA expression and protein production in vivo 
from guinea pigs following induction of tuberculous pleurisy.  BCG-vaccinated guinea 
pigs were injected with heat killed M. tuberculosis H37Rv 5 wks post-vaccination and 
fluid in the pleural space was aspirated at daily intervals.  Panel (A) total RNA was 
collected from pleural exudate cells, reverse transcribed to cDNA, and real-time PCR 
using SYBR Green was performed.  Fold induction levels were derived from 
normalizing the CCL5 Ct values against HPRT values, and further normalizing against 
values derived from resident pleural cells obtained from BCG-vaccinated pleuritic-free 
animals.  Panel B: CCL5 protein levels were measured in pleural fluids by ELISA.  Data 
are representative of the mean + SEM of 3-4 separate animals.  An asterisk represents 
significance (p < 0.05) from day one.  A double asterisk represents significance (p < 
0.05) above all days.  Significance was determined using ANOVA.  
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We examined the CCL5 response in vitro to M. tuberculosis infection in three distinct 
leukocyte populations from BCG-vaccinated and naïve guinea pigs, and in vivo during  
tuberculous pleurisy.  For the first time, an ELISA assay was developed and used to 
quantify secreted guinea pig CCL5 protein production by infected macrophages. 
We show that alveolar macrophages infected with M. tuberculosis have an 
enhanced expression of CCL5 mRNA regardless of vaccination status (fig. 18A).  These  
results are similar to previous work in our lab, which demonstrated minimal effects of 
prior vaccination on expression of another CC chemokine, CCL2 (MCP-1), at the 
mRNA level in H37Rv-infected alveolar macrophages isolated from BCG-immunized 
and non-immunized guinea pigs (118).  At the protein level, CCL5 was significantly 
elevated in alveolar macrophages harvested from BCG-immunized guinea pigs 
compared to non-immunized animals at 72 h post-M. tuberculosis infection (fig. 18B).  
This trend seems to replicate a previous study displaying enhanced levels of CXCL8, a 
member of the alpha (CXC) chemokine family, in alveolar macrophages harvested from 
BCG-vaccinated compared to naïve guinea pigs and infected with M. tuberculosis (118).  
The levels of CCL5 protein in our study were similar to CCL5 levels present in M. 
tuberculosis H37Ra-infected human alveolar macrophages in vitro at 72 h in one study 
(167).  However, in another study, CCL5 protein exhibited 10-fold higher levels in 
supernatants from H37Ra- and H37Rv-infected human alveolar macrophages (174).  
One explanation for the discrepancy in this last experiment is that the MOI used was 
100-fold higher, suggesting that a large bacterial load may be needed to elicit higher 
(ng/ml) levels of CCL5 protein from alveolar macrophages.  The absence of published 
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murine and rabbit studies analyzing CCL5 production from alveolar macrophages 
infected with M. tuberculosis prevents us from making a more complete comparative 
analysis.   
 Resident peritoneal macrophages were infected with M. tuberculosis to compare 
their CCL5 response to that of alveolar macrophages.  Resident peritoneal macrophages 
harvested from BCG-vaccinated guinea pigs had elevated levels of CCL5 mRNA in 
response to virulent infection, whereas CCL5 mRNA levels in macrophages isolated 
from naive animals were unaffected by M. tuberculosis infection.  In this cell type, 
CCL5 mRNA was immediately enhanced, though not significantly, at 2 h post-
incubation (0 h) with M. tuberculosis and followed a kinetic pattern peaking at 48 h 
post-infection.  Significant differences between peritoneal macrophages harvested from 
BCG-vaccinated and naive guinea pigs were apparent as early as 6 h, and continued 
through 48 h post-infection (fig. 19A).  These observations are similar to previous 
research done in our laboratory analyzing thioglycollate-induced peritoneal macrophages 
infected with M. tuberculosis (85).  These earlier studies demonstrated a significant up-
regulation of CCL5 mRNA in infected peritoneal exudate macrophages harvested from 
BCG-vaccinated guinea pigs compared to naïve animals, and confirmed the absence of a 
response by infected macrophages from naive animals.  Guinea pig CCL5 protein 
production by M. tuberculosis-infected resident peritoneal macrophages from BCG-
vaccinated animals exhibited similar kinetics to mRNA levels, with concentrations 
reaching significant differences at 48 and 72 h (fig. 19B).  The absolute levels of CCL5 
protein were substantially higher by more than 10-fold in resident peritoneal 
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macrophages isolated from BCG-vaccinated guinea pigs compared to alveolar 
macrophages.    
The contribution of antigen-sensitized lymphocytes derived from M. bovis BCG 
vaccination was analyzed by measuring the expression of CCL5 in M. tuberculosis-
infected splenocytes.  This mixed cell population has been characterized previously 
when we reported a significant elevation of TNFα protein production in splenocytes 
obtained from BCG-vaccinated versus naive guinea pigs (106).  In this study we 
demonstrate significant enhancement in CCL5 mRNA expression in uninfected (time = 0 
h) splenocytes harvested from BCG-vaccinated guinea pigs compared to naive animals 
(Figure 20A).  These results are similar to previous findings of increased CCL5 mRNA 
in CD8+ T cells from lymph nodes in guinea pigs (98), and agree with previous data 
showing increased levels of CCL5 mRNA expression in murine memory T lymphocytes 
(191, 204).  Significant differences in CCL5 mRNA levels between naive and vaccinated 
infected splenocytes were observed at 24 h (fig. 20A), but the levels of fold induction 
were drastically reduced compared to infected macrophages (fig. 18A and 19A).  
However, CCL5 protein production (~1000 pg/ml) appeared as early as 6 h post-
infection in both splenocyte groups (fig. 20B) suggesting constitutive production of 
CCL5, which was independent of vaccination status.  After day one, infected splenocytes 
from BCG-vaccinated animals displayed enhanced levels of secreted CCL5 protein 
whereas naive splenocytes produced relatively constant levels throughout the culture 
period.  Rapid CCL5 secretion may be due to the presence of T lymphocytes, especially 
memory CD8+ T cells.  This theory is supported by findings that CCL5 is stored in 
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unique secretory compartments in memory and effector human CD8+ T cells (30).  
Granules containing CCL5 in humans during chronic gastritis were seen more often in 
CD8+ T cells than in CD4+ T cells (143).  It has also been shown by Dorner et al. that a 
greater percentage of murine CD8+ T cells produce CCL5 compared to CD4+ T cells on 
a single cell basis (55).  Future studies will identify the precise cellular types responsible 
for the production of CCL5 in the spleens of guinea pigs.      
A model of tuberculous pleurisy in the guinea pig was developed in our 
laboratory to study the cells and cytokines involved in the development of a 
mycobacterial-specific inflammatory exudate in a previously vaccinated animal (8, 154).  
Pleural tuberculosis is the most common extrapulmonary manifestation of tuberculosis 
in humans (138) and generally resolves without therapy (164) suggesting that the 
immune response in the pleural space is sufficient.  In the present study, we have shown 
a significant increase in CCL5 mRNA expression from the pleural exudate cells (fig. 
21A) and in secreted CCL5 protein in the pleural fluid (fig. 21B) of BCG-vaccinated 
guinea pigs following induction of tuberculous pleurisy.  CCL5 mRNA levels were 
elevated from day one following induction during infection compared to uninduced 
resident pleural cells, and peaked on day 4.  Similarly, Fine, et al. saw increased CCL5 
mRNA peaking at 72 h and heightened levels of CCL5 protein throughout the 
experiment when they induced pleurisy in mice with methylated BSA, complete 
Freund’s adjuvant, and M. tuberculosis dried cell walls (60).  CCL5 protein production 
peaked at 24 h in their experiment, which coincided with increased numbers of T 
lymphocytes and macrophages from 24 to 48 h.  Due to the absence of time intervals 
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past 72 h, it is difficult to compare their results with ours.  However, their peak levels of 
CCL5 mRNA correlated with our significantly enhanced levels at 72 h.  The high 
production of CCL5 in the pleural inflammatory response could reflect the activity of 
numerous leukocyte and non-leukocyte populations.  The primary cells involved in 
delayed-type hypersensitivity reactions include T lymphocytes and macrophages, which 
are both producers of CCL5 and chemotactic to CCL5.  Recently it has been 
demonstrated that normal pleural mesothelial cells can express and secrete CCL5 in the 
presence of TNFα, and this effect is synergistically enhanced with IFNγ (92).  This 
synergistic effect could have resulted in enhanced CCL5 mRNA stability suggesting an 
explanation for the prolonged elevated levels of CCL5 mRNA throughout the five days 
in our studies.  It has also been shown that TNFα and IFNγ can induce CCL5 secretion 
in human endothelial cells (122) and lung fibroblasts (195).  Since previous studies have 
demonstrated an induction of TNFα and IFNγ during tuberculosis pleurisy in humans 
and guinea pigs (8, 18, 19), it is reasonable to expect high levels of CCL5 throughout the 
inflammatory process, which is precisely what we observed (Figure 21B). The continued 
presence of CCL5 in tuberculous pleurisy may be beneficial for the development of 
delayed-type hypersensitivity reaction due to its ability to attract 
monocytes/macrophages and T lymphocytes (142, 175), especially of the Th1 phenotype 
(209).  Chensue et al. have demonstrated the importance of CCL5 by neutralizing it with 
anti-CCL5, thus resulting in a diminished PPD-granuloma size in mice (35).  At higher 
concentrations, CCL5 has been shown to activate T lymphocytes and induce 
proliferation in a mitogen-like manner (11, 14), as well as acting like an adjuvant to 
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induce proliferation of memory T lymphocytes (95).  Future studies will be focused on 
dissecting the role of CCL5 in tuberculous pleurisy by neutralizing its effects in vivo and 
analyzing granuloma formation and leukocyte influx.   
 In summary, we know from previous studies that BCG provides solid protection 
against M. tuberculosis infections in the guinea pig (185, 186).  Here we demonstrate 
enhanced expression and production of CCL5 in response to in vitro M. tuberculosis 
infection in three distinct leukocyte populations obtained from an antigen-induced 
inflammatory exudate in BCG-vaccinated guinea pigs compared to naive animals.  
Similarly, we observed elevated CCL5 protein and mRNA levels in the immune 
response against M. tuberculosis antigens as it progressed in pleuritic guinea pigs.  
Taken together, these results suggest that CCL5 is important in eliciting rapid effective 
immune responses against M. tuberculosis.
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CHAPTER VI 
THE ROLE OF CCL5 DURING TUBERCULOUS PLEURISY IN THE GUINEA 
PIG MODEL 
 
INTRODUCTION 
Tuberculous pleurisy remains one of the leading extrapulmonary manifestations 
of tuberculosis infections (3, 180).  The development of the HIV/AIDS pandemic has 
resulted in an increase number of tuberculosis cases and, in some studies, increased 
cases of tuberculous pleurisy (67, 75).   It is believed that this extrapulmonary disease 
usually arises as a result of a rupture of a tubercle in the subpleura from the primary 
infection leading to spewing of caseous discharge into the pleural space.  This occurs in 
patients recently sensitized to mycobacterial antigens, resulting in a prompt, localized 
cell-mediated immune response in the pleural space and the appearance of acute 
symptoms (57).  Untreated patients with tuberculous pleurisy usually resolve the 
infection within a month, suggesting that this is a self-limiting form of tuberculosis (57, 
109) and that the intrapleural immune response is protective.  Therefore, this localized, 
antigen-specific inflammatory response might provide a useful approach to 
understanding the role of a particular cytokine/chemokine during a protective immune 
response elicited against M. tuberculosis.   
 Previous studies have attempted to elucidate the cytokines/chemokines involved 
during this extrapulmonary tuberculous manifestation.  In the concentrated pleural fluid 
(183) which accumulates throughout the course of tuberculous pleurisy, neutrophils 
 95
predominate during the early phase of disease with primarily lymphocytes in late 
effusions (109).  IFNγ, TNFα, IL-1β, and TGFβ have been found in tuberculous pleural 
fluid, pleural macrophages, and/or mesothelial cells (18, 60, 83, 100, 183) in response to 
M. tuberculosis.  Previous studies have also demonstrated a plethora of chemokines, 
including CXCL-8, CCL5, and CCL2, in association with tuberculous pleurisy (60, 92, 
135, 149).   
 Chemokines partake in various biological activities, including chemotaxis of T 
lymphocytes (166, 175), macrophages (27), and neutrophils (119), CD4+ T lymphocyte 
differentiation (217), enhancing T lymphocyte proliferation and IFNγ production (193), 
activating leukocyte reactive oxygen intermediates (36, 170), and granuloma formation 
(35, 48).  These activities suggest an important role of these molecules during the 
delayed-type hypersensitivity reaction elicited in response to M. tuberculosis.   
 A guinea pig model of tuberculous pleurisy has been developed previously (154).  
In this study, the role of CCL5 was examined during tuberculous pleurisy in the guinea 
pig.  The effect of altering CCL5 function by intrapleural injection of rgpCCL5 and anti-
rgpCCL5 on the migration of leukocyte populations, cytokine/chemokine mRNA levels 
in pleural cells and within granulomas, and the histological nature of granulomas was 
examined.  Together, these data contribute to our understanding of the role of CCL5 in 
the development and expression of a protective intrapleural immune response.     
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MATERIALS AND METHODS 
 
Purified anti-rgpCCL5 IgG preparation.  HiTrapTM Protein A HP (Amersham 
Biosciences, Uppsala, Sweden) columns were used to isolate rabbit anti-rgpCCL5 IgG 
from antiserum following the manufacturer’s instructions.  Isolated IgG samples were 
verified on SDS-PAGE gels under reducing and native conditions.  Reducing conditions 
resulted in the presence of two bands, heavy (50kDa) and light (25kDa) chains, with one 
band (150kDa) present under native conditions.  After verification of the isolation of 
IgG, the antibodies were passed through PD-10 desalting columns (Amersham 
Biosciences) and tested for neutralization properties via chemotaxis assays.   
Animals and vaccination.  Specific-pathogen-free, outbred, male and female 
Hartley guinea pigs from Charles River Breeding Laboratories, Inc. (Wilmington, MA) 
were housed in polycarbonate cages within an air-filtered environment under a 12 h 
light-dark cycle.  Food (Ralston Purina, St. Louis, MO) and tap water were supplied to 
the animals ad libitum.  Five-week old guinea pigs were vaccinated via intradermal 
injection of 0.1ml (103 CFU) of viable Mycobacterium bovis BCG (Danish 1331 strain, 
Statens Seruminstitut, Copenhagen, DK) into the left inguinal region.  All procedures 
were reviewed and approved by the Texas A&M University Laboratory Animal Care 
Committee.   
Mycobacterial preparations and pleurisy induction.  M. tuberculosis H37Rv 
(ATCC 27294; American Type Culture Collection, Manassas, VA) and H37Ra (ATCC 
25177) suspensions stored at –80°C were rapidly thawed, vortexed, and sonicated for 
60s with an Ultrasonics sonicator (Heat Systems-Ultrasonics, Inc., Plainview, NY) at an 
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output setting of 8.0 to disperse clumps.  Bacteria were heat-killed by incubation at 80°C 
for 2 h and resuspended in sterile, endotoxin free 0.9% sodium chloride solution (Sigma, 
St. Louis, MO) at a concentration of 2 x 107 CFU/ml.  Five weeks after BCG-
vaccination, guinea pigs were anesthetized by an intramuscular injection in the hind leg 
with 9-15mg/kg of ketamine and 0.75-1.25mg/kg of xylazine, and injected bilaterally 
into the pleural space with 1ml heat-killed M. tuberculosis in combination with either 
0.9% sodium chloride solution, rgpCCL5 (6.7µg/side), rabbit IgG control (300µg/side) 
(ICN Pharmaceuticals, Inc., Aurora, OH), or rabbit anti-rgpCCL5 (300µg/side) 
following a previous protocol (154).  
Necropsy and pleural cell isolation.  Guinea pigs were anesthetized daily with 
the ketamine/xylazine mixture and 5 animals per group were given bilateral injections of 
150µl of sterile PBS, rgpCCL5 (6.7µg /side), rabbit IgG control (300µg/side), or rabbit 
anti-rgpCCL5 (300µg/side).  Four guinea pigs were not anesthetized after day 0 and 
were used as controls for the effect of daily anesthesia on the progression of tuberculosis 
pleurisy.  At day 4, all guinea pigs were euthanized with an intraperitoneal overdose 
injection of sodium pentobarbital (100mg/ml) (Sleepaway Euthanasia Solution; Fort 
Dodge Laboratories, Inc., Fort Dodge, IA).  The abdominal cavity was opened 
aseptically and fluid was collected from the pleural cavity by making a small incision in 
the top of the diaphragm and aspirating fluid with a syringe and 26gauge1 needle.  After 
the majority of fluid was obtained the diaphragm was cut further until exposing the 
whole pleural cavity and any residual fluid was further aspirated.  At this time, the 
severity of disease was scored according to the presence of granulomas as described in 
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Table 1.  The groups receiving rabbit anti-rgpCCL5, rabbit IgG, and the control (with no 
anesthesia) had the pleural cavity washed with 10ml of PBS after the initial pleural fluid 
was collected.  The pleural exudate was centrifuged at 200 × g for 15 min, and the fluid 
was transferred to a 15ml conical tube and centrifuged at 1,400 × g for 20 min to remove 
any remaining cells and stored at –80°C.  Erythrocytes were lysed in the pleural cells 
using ACK lysis buffer (0.14M NH4Cl, 1.0mM KHCO3, 0.1mM Na2EDTA [pH 7.2 – 
7.4]) and washed twice with PBS.  Pleural cells were then resuspended in 1ml of RPMI 
1640 complete medium and enumerated on a hemacytometer by the trypan blue 
exclusion method (Gibco Life Technologies, Grand Island, NY).     
Splenocyte preparation and T lymphocyte isolation.  Spleens were removed 
and placed in RPMI-1640 medium supplemented with 10% FBS, 10µM 2-
mercaptoethanol, and 2µM L-glutamine (RPMI complete medium (C-RPMI)).  Spleens 
were homogenized and erythrocytes were lysed with ACK lysis buffer.  Splenocytes 
were washed twice with PBS and resuspended in 2 ml of C-RPMI.  T lymphocytes were 
further isolated by incubating the cells on a nylon wool column for 1 h at 37°C with 5% 
CO2 following manufacturer’s instructions (Polysciences Inc., Warrington, PA). The 
nonadherent cells were collected as the column was washed with 50ml of warm C-
RPMI.  Cells were centrifuged at 200 ×g for 10 min, followed by a PBS wash, and 
resuspended in RPMI + 0.1% bovine serum albumin (RPMI-BSA) at 5 × 106 cells/ml.   
T lymphocyte chemotaxis.  Chemotaxis was performed using ChemoTx 
(Neuroprobe, Inc., Gaithersburg, MD) disposable chemotaxis systems containing 5µm 
pore size polycarbonate filters, following modified instructions from the manufacturer.  
 99
Dilutions of rgpCCL5 and anti-rgpCCL5 were made in RPMI-BSA.  Solutions 
containing anti-rgpCCL5 and rgpCCL5 were incubated for 30 min at 37°C preceding the 
addition of 300µl/well in a 96-well plate.  The polycarbonate filter was then placed on 
the plate and checked to ensure that the fluid in each well was in contact with the filter.  
The cells were then added to the top of the filter in a 50µl volume containing 2.5 × 105 
cells/well.  Chemotaxis was performed at 37°C in 5% CO2 for 2 h.  The fluid on top of 
the filter was aspirated and cotton swabs were used to wipe off any cells remaining on 
the top of the filters.  Plates were centrifuged for 430 × g for 10 minutes to dislodge any 
remaining cells bound to the underside of the filter.  The filter plate was removed and 
150ul aspirated from each well.  A tetrazolium salt, 3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma), was added at 5mg/ml to each well and 
allowed to incubate for 2 h at 37°C in 5% CO2.  Plates were centrifuged at 140 × g for 5 
min and supernatants were aspirated.  Warm lysis buffer (50% 2-2 Dimethylformamide 
and 20% SDS at pH 4.7) was added to each well and allowed to incubate for 4 h at 37°C 
and 5% CO2.  This colorimetric assay was then read at 570nm using a Dynatech MR5000 
automated plate reader and analyzed with Biolinx Software, version 2.1 (Dynatech 
Laboratories, Inc., Chantilly, VA). 
Flow cytometry.  Pleural exudate cells were examined for cell surface 
expression of CD3, CD4, CD8, and MHC class II by flow cytometry as previously 
described (86).  Briefly, 7.5 × 105 cells were blocked with normal goat IgG (1 mg/ml; 
Sigma) for 10 minutes, then washed with HBSS containing 10% FBS and stained with 
mouse anti-guinea pig CD3 (1:500), with mouse anti-guinea pig CD4 (1:500), with 
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mouse anti-guinea pig CD8 (1:1000), or with mouse anti-guinea pig MHC II (1:10; all 
from Serotec, Raleigh, NC) for 1 h on ice while shaking.  Cells were washed 3 times in 
HBSS containing 10% FBS.  The pellet was resuspended in FITC-conjugated AffiniPure 
goat anti-mouse IgG (1:50; Jackson ImmunoResearch Laboratories, Inc., West Grove, 
PA), and incubated for 1 h on ice while shaking.  The cells were washed 2 times in 
HBSS containing 10% FBS, and resuspended in 300 µl HBSS containing 1% 
paraformaldehyde.  The proportions of positive cells were determined with a 
FACSCalibur flow cytometer and Cell Quest software (Becton Dickinson, San Jose, 
CA).  Controls included unstained and secondary antibody only stained cells, and the 
positive population was set such that less than 2% of the negative control was positive 
for green fluorescence.    
Cellular differentiation.  Pleural cells were resuspended at 2 x 106 cells/ml and 
80µl of cells were centrifuged onto silanated glass slides (CSA-100; PGC Scientifics, 
Gaithersburg, MD) at 140 × g for 5 min (Cytospin 2; Shandon Southern Instrument, Inc., 
Sewickley, PA).  Diff-Quik (Dade Behring Inc., Newark, DE) stains were performed on 
the cells and 600 cells/slide were analyzed using light microscopy to determine the 
relative proportions of different leukocyte populations.  Dr. Karen Russell from Texas 
A&M University Department of Veterinary Pathobiology performed all of the 
differential counts without knowledge of the treatment groups associated with the 
studies.    
Lymphoproliferation.  Pleural cells were incubated in a 100µl volume (2 × 106 
cells/ml) in 96-well plates at 37°C with 5% CO2 with or without PPD (12.5 or 25 µg/ml) 
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for 96 h.  [H3] thymidine was added at 1 µCi/well for the final 6 h of incubation.  
Spontaneous proliferation was determined by plating the cells immediately (ex vivo) 
with [H3] thymidine for 6 h.  Pleural cells were harvested onto glass fiber filters, and 
proliferation was determined by the number of counts per minute with a liquid 
scintillation counter (LS8000; Beckman Instruments, Inc., Fullerton, CA).  Data are 
presented as the mean cpm from each group for spontaneous proliferation and mean 
delta (PPD-stimulated cpm – unstimulated cpm) cpm for antigen-specific proliferation.  
RNA isolation and real-time PCR on cytokine mRNA.  RNA from pleural 
cells was obtained by centrifuging 5 x 105 cells, aspirating the supernatant, and lysing 
the cells with Buffer RLT (QIAGEN, Valencia, CA).  Total RNA was isolated using the 
RNeasy kit (QIAGEN) with the addition of Rnase-free DNase (QIAGEN) according to 
the manufacturer’s instructions.  Granulomas from the pleural cavity were obtained and 
placed in ≥ 5 volumes of RNAlater (Ambion, Austin, TX) and stored at 4°.  The 
PowerGen 125 PCR tissue homogenizing kit (Fischer Scientific, Pittsburgh, PA) was 
used to homogenize the granulomas.  Total RNA from homogenates was isolated using 
RNeasy kit (QIAGEN).  Reverse transcription was performed on total RNA using 
TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA).  
Negative controls were performed to ensure PCR amplification of cDNA was not due to 
contaminating genomic DNA.  Real-time PCR analysis was performed on the cDNA 
using SYBR Green I (Applied Biosystems) following a previously published protocol 
(118).  Primer Express software (Applied Biosystems) was used to design primer 
sequences (see Table 2).  The sequences for TNFα, CXCL8, and CCL2 primers were 
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previously described (8, 118).  Real-time PCR was performed using the Applied 
Biosystems Prism 7500 sequence detector following the manufacturer’s instructions.  
Results were expressed as fold induction levels of mRNA, which was determined by 
normalizing cytokine/chemokine threshold cycle (Ct) values against HPRT values.  This 
was further normalized against Ct values from pleural cells isolated from pleurisy-free 
(not given M. tuberculosis antigens) BCG-vaccinated guinea pigs.   
Histopathology.  Granulomas from the pleural cavity of pleuritic guinea pigs 
were obtained and fixed in 10% buffered formalin.  Tissues were embedded in paraffin, 
sectioned at 5µm, and stained with hematoxylin and eosin (H & E) for histopathological 
examination and Ziehl-Neelsen staining to determine bacterial burdens within the 
granulomas.  All tissue sections were scored based on their overall inflammatory 
severity/presence of cells or bacteria according to Table 4.  The grading was performed 
by Dr. John Mackie, Veterinary Pathologist from Idexx Laboratories (Australia) without 
knowledge of the treatment group from which the samples were obtained. 
Statistical analysis.  For the chemotaxis assay, analysis of variance followed by 
Duncan’s post hoc analysis was used to determine the statistical significance between 
rgpCCL5 concentrations.  In the pleurisy studies, the same tests were used to compare 
the statistical significance of differences between guinea pigs treated with saline, 
rgpCCL5, IgG control, anti-rgpCCL5, or control without daily anesthesia for 
cytokine/chemokine mRNA expression levels.  A two-tailed Student’s t-test was used to 
determine statistical significance of differences between the rgpCCL5 versus saline 
groups, the anti-rgpCCL5 versus IgG control groups, and the saline versus control 
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groups (no anesthesia after day 0).  All differences were considered significant at a 95% 
confidence interval.  The statistical tests were performed using SAS software (release 
8.01; SAS Institute, Inc., Cary, NC).   
 
RESULTS 
Neutralization properties of anti-rgpCCL5.  Figure 22 illustrates chemotactic 
effects of rgpCCL5 on T lymphocytes isolated from BCG-vaccinated guinea pigs (Fig. 
22A).  Significant migration of T lymphocytes was observed at concentrations of 
rgpCCL5 greater than 125ng/ml.  Neutralization of the chemotactic effect of rgpCCL5 
(375ng/ml) was detected with a concentration gradient of anti-rgpCCL5 (Fig. 22B) with 
complete neutralization apparent at 100µg/ml of anti-rgpCCL5 after 2 h of chemotaxis. 
Severity of tuberculous pleurisy.  The role of gpCCL5 during tuberculous 
pleurisy was assessed by injecting heat-killed M. tuberculosis H37Rv, and giving daily 
intrapleural injections of saline, rgpCCL5, rabbit IgG control, or anti-rgpCCL5.  The 
effect of daily anesthesia was evaluated by characterizing pleurisy from a group of BCG-
vaccinated guinea pigs to which anesthesia had been given on day 0 for pleurisy 
induction.  Figure 23 describes the disease severity score, based upon the criteria in 
Table 1, and fluid accumulation in the pleural cavities of BCG-vaccinated guinea pigs 
after 4 days with tuberculous pleurisy.  Guinea pigs receiving daily injections of 
rgpCCL5 (6.25µg/side/day) presented with similar disease severity to those given daily 
injections of sterile saline (Fig. 23A).  However, there was a significant (p < 0.05)  
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Figure 22:  Chemotactic properties of rgpCCL5 to T lymphocytes and neutralization 
properties of anti-rgpCCL5.  Cell migration was determined using the MTT viability 
assay after the cells were dislodged from the filters.  Panel A displays migration of T 
lymphocytes from BCG-vaccinated guinea pigs to various concentrations of rgpCCL5.  
Results are representative of the mean + SEM for three experiments, each containing 
quadruplicate wells per concentration tested.  * Significant differences (p < 0.05) were 
seen in migration with rgpCCL5 concentrations compared to media alone using 
ANOVA.  Panel B represents chemotaxis of T lymphocytes obtained from naive guinea 
pigs.  Anti-rgpCCL5 IgG was incubated with rgpCCL5 for 30 min before addition to 96-
well plate.  Results are displayed as the mean + SEM of quadruplicate wells from one 
experiment.
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Disease severity rankinga Characteristics of tuberculous pleurisy
1 Inflamed diaphragm/connective tissue; no granulomas
2 few/small granulomas
3 medium granulomas
4 severe granulomas
Table 1:  Ranking of tuberculous pleurisy post-4 days induction
     a Severity was determined by the size and quantity of granulomas inside the pleural cavity of 
BCG-vaccinated guinea pigs 4 days after pleurisy-induction.
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Figure 23:  The impact of altering local gpCCL5 activity on the severity of pleuritis in 
the guinea pig.  Guinea pigs were injected into the pleural space with heat-killed M. 
tuberculosis (H37Rv).  On day 4 of tuberculous pleurisy, the animals were euthanized 
and pleural fluid was aspirated and quantified.  Severity was determined using the 
ranking system described in Table 1.  Data in panel A represent the means + SEM of 
five animals.  Panel B and C represent the means + SEM of four animals.  Significance 
(* p < 0.05, ** p < 0.01) between treatment groups was determined by the Student’s t 
test. 
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Elevation in the volume of pleural fluid obtained from the pleural cavity of guinea pigs 
given rgpCCL5 compared to saline alone.  In Fig. 23B, guinea pigs receiving anti- 
rgpCCL5 (300µg/side/day) presented with significantly (p < 0.01) elevated pleural fluid 
levels and enhanced severity compared to animals given daily bilateral injections in the 
pleural cavity of rabbit IgG control (300µg/side/day).  The effect of daily anesthesia on 
severity and fluid accumulation in animals infected with tuberculous pleurisy is 
illustrated in Fig. 23C.  No significant difference was present between the two treatments 
groups in either disease severity or pleural fluid. 
Effect of altering local CCL5 activity on leukocyte populations in the pleural 
cavity during tuberculous pleurisy.  At 4 days post-pleurisy induction, pleural fluid 
was aspirated from the cavity and centrifuged to obtain pleural cells.  Figure 24 
illustrates the effect of adding exogenous CCL5 or neutralizing local CCL5 on the 
proportions of CD3+, CD4+, and CD8+ T lymphocytes and MHC class II expressing cells 
as measured by flow cytometry.  In Fig. 24A, a significant reduction (p < 0.05) of 15-
20% was observed in the proportions of CD3+ and CD4+ T lymphocytes from pleurisy-
infected BCG-vaccinated guinea pigs treated with daily injections of rgpCCL5.  CD8+ T 
lymphocytes appeared unaltered by the presence of exogenous rgpCCL5.  In Fig. 24B 
and 24C, leukocytes from the pleural fluid were mixed with cells obtained from a 10ml 
PBS wash of the pleural cavity.  Fig 24B demonstrates minimal differences in the 
proportion of T lymphocytes between animals treated with anti-CCL5 compared to 
control antibody isotype (IgG) alone.  However, cells expressing MHC class II were 
significantly diminished (p < 0.05) in guinea pigs given daily injections of anti-rgpCCL5 
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Figure 24:  The effect of CCL5 on T cell subpopulations and MHC II cells.  Pleural cells 
were isolated on day 4 from pleurisy-induced BCG-vaccinated guinea pigs.  The cells 
were labeled with anti-CD3, anti-CD4, anti-CD8, and anti-MHC class II.  All data 
represent the mean + SEM of 3-4 guinea pigs per treatment group.  Panel A represents 
saline versus rgpCCL5-treated pleuritic guinea pigs.  Anti-rgpCCL5 compared to control 
IgG-treated groups were represented in panel B, and panel C demonstrates the effect of 
daily anesthesia (saline) versus control (anesthesia only given on day 0) on T cell 
population in the pleural effusions.  Labeled leukocytes were then quantified by flow 
cytometry.  Significance (* p < 0.05, ** p < 0.01) was determined using the Student t 
test.
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Compared to control IgG antibody.  Pleuritic guinea pigs not anesthetized daily (control)  
displayed significantly diminished levels of CD3+ (p < 0.05) and CD4+ (p < 0.01) T 
lymphocytes (Fig. 24C) compared to saline treated groups with daily anesthesia.   
Pleural cells were centrifuged onto glass slides and stained with Diff-Quik to 
enumerate different leukocyte populations, and the results are illustrated in Fig. 25.  In 
Fig. 25A, lymphocytes were significantly diminished (p < 0.05) in animals treated with 
rgpCCL5 compared to saline, while treatment with rgpCCL5 resulted in a minimal 
differences in the other leukocyte populations compared to saline treated animals.  In 
Fig. 25B, the pleural cells were obtained by mixing cells from the initial pleural fluid 
aspirate and cells from a 10ml PBS pleural wash.  Macrophage populations were 
significantly depressed (p < 0.05) in animals treated with anti-rgpCCL5 compared to 
control antibody.  An increase in the percentage of eosinophils was apparent in animals 
exposed to anti-rgpCCL5 compared to isotype control.  Minimal differences were 
apparent regarding the other leukocyte populations.  In Fig. 25C pleurisy-induced guinea 
pigs without daily anesthesia (control) presented percentages of leukocyte populations 
quite similar to the saline-treated group.        
Proliferation of pleural cells.  Pleural cells isolated from guinea pigs 4 days 
post-induction were analyzed for proliferative activity.  As illustrated in Fig. 26, no 
difference was seen in spontaneous proliferation from cells isolated from rgpCCL5 or 
saline treated animals (Fig. 26A).  Figure 26B shows a significant suppression (p < 0.05) 
of spontaneous proliferation ex vivo in cells isolated from anti-rgpCCL5-treated, 
compared to control IgG-treated, guinea pigs.  In Fig. 26C, PPD-specific (25µg/ml)  
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Figure 25:  Cellular differentiation of pleural cells between treatment groups.  On day 4 
of tuberculous pleurisy, pleural cells were extracted from BCG-vaccinated guinea pigs 
and centrifuged onto slides.  Diff-Quik staining was performed on the slides to 
determine the proportions of different leukocyte subpopulations using light microscopy.  
Data represent the mean + SEM of 3-4 animals per group.  Panel A exhibits cellular 
populations in saline-treated compared to rgpCCL5-treated.  Panel B compares cellular 
populations in anti-rgpCCL5 treated and IgG control treated groups.  The effect of daily 
anesthesia and injections on cell populations in the pleural effusion is demonstrated in 
panel C, where the control group (receiving only one day with anesthesia and injection) 
is compared to the saline group (given daily injections and anesthesia).  Significance (* p 
< 0.05) was determined using the Student’s t test.  Neut, neutrophil; Lymp, lymphocytes; 
Mac, macrophages; Eos, eosinophils; Kurl, Kurloff cells; R Lym, reactive lymphocytes. 
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Figure 26:  Effect of modifying local activity of CCL5 on pleural lymphocyte 
proliferation.  Cells were obtained from the pleural cavity 4 days after induction.  Panel 
A and B: cells were cultured immediately with [3H] thymidine for 6 h to determine 
proliferative activity within the pleural cavity.  Panel C: PPD-specific proliferation was 
determined in saline and rgpCCL5 treated guinea pigs after 72 h of antigen stimulation 
(PPD) with the addition of [3H] thymidine the last 6 h.  Results represent the mean cpm 
+ SEM of 3-4 animals per groups performed in triplicate.  Significance (* p < 0.05) is 
depicted by an asterisk using Student’s t test. 
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Proliferation was significantly elevated (p < 0.05) in pleural cells isolated from 
rgpCCL5-treated compared to saline-treated animals. 
Cytokine/chemokine mRNA expression in pleural cells.  TNFα, IL-1β, IL-
12p40, IFNγ, CCL2, CCL5, and CXCL8 mRNA were analyzed by isolating RNA from 
pleural cells obtained from BCG-vaccinated guinea pigs 4 days after pleurisy induction.  
Total RNA was reverse transcribed into cDNA and gene expression was determined 
using real-time PCR with primers described in Table 2, and the results are illustrated in 
Figs. 27-29.  Expression of IFNγ mRNA in pleural cells was ~ 7 fold greater than all 
other cytokine levels tested in the saline treated group (Fig. 27A).  On the contrary, 
animals treated with rgpCCL5 had similar IFNγ and IL-12p40 mRNA levels.  Among 
the chemokines tested, CCL5 was expressed at levels 8 fold higher compared to CCL2 
and CXCL8 expression (Fig. 27B).  There was an absence of CCL2 expression in cells 
isolated from the pleural cavity of animals with tuberculous pleurisy (Fig. 27B) 
compared to pleural cells isolated from BCG-vaccinated guinea pigs without pleurisy.  
Comparative studies between treatment groups of pleuritic guinea pigs demonstrated 
significantly lower IFNγ (p < 0.05) and CCL5 (p = 0.057) mRNA levels in guinea pigs 
treated with rgpCCL5 compared to saline (Fig. 27A and 27B).  Enhanced levels of IL-1β 
(p < 0.05) and IL-12p40 (p < 0.05) were detected in pleural exudate cells from pleuritic 
guinea pigs given daily injections of rgpCCL5 compared to saline alone (Fig. 27A).  In 
Fig. 28A, mRNA from pleural cells obtained from initial pleural aspiration and PBS 
wash of the pleural cavity from guinea pigs given daily injections of isotype control 
(IgG) demonstrated enhanced IFNγ mRNA levels, like the saline group, at twice the  
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Gene Forward Primera Reverse Primera
TNF alpha 5' - TTGATGGCAGAGAGAAGGTTGA - 3' 5' - CCTACCTGCTTCTCACCCATACC - 3'
IL-1 beta 5' - GGAGTCTCTACCAGCTCAACTTGG - 3' 5' - GCCCAGGCAACAGCTCTC - 3'
IL-12p40 5' - CCATTCGCTCCACGATGAG - 3' 5' - CCACAGTTTCATGCCACAAGA - 3'
IFN gamma 5' - GTTCCTCTGGTTCGGTGACA - 3' 5' - ATTTCGGTCAATGACGAGCAT - 3'
CCL5 5' - CCTTGCTTCTTTGCCTTGAAA - 3' 5' - CTGGCCCACTGCTTAGCAAT - 3'
CCL2 5' - CGAATGTTCAAAGGCTTTGAGGT - 3' 5' - TTGCCAAACTGGCACCAGAGAA - 3'
CXCL8 5' - CAGCTCCGAGACCAACTTTGT - 3' 5' - GGCAGCCTTCCTGCTCTCT - 3'
HPRT 5' - AGGTGTTTATCCCTCATGGACTAATT - 3' 5' - CCTCCCATCTCCTTCATCACAT - 3'
Table 2:  Primers used for real-time PCR  
 a  Primers express software was used to design sequences for guinea pig genes to use in the real-time PCR assay using SYBR Green
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Figure 27:  Effect of rgpCCL5 on cytokine and chemokine mRNA in pleural cells 
obtained from BCG-vaccinated guinea pigs 4 days post induction.  Total RNA was 
isolated, reverse transcribed, and cDNA was analyzed by real-time PCR.  Results were 
expressed as fold induction of mRNA, which was determined by normalizing 
cytokine/chemokine threshold cycle (Ct) values against HPRT values.  This was further 
normalized against mRNA from pleural cells obtained from pleurisy-free (no antigen 
injected) animals.  Data represent mean + SEM of 3-4 animals per group.  Panel A:  
exhibits data comparing cytokine mRNA levels in saline-treated versus rgpCCL5-treated 
groups.  Panel B:  exhibits data comparing chemokine mRNA levels in saline-treated 
versus rgpCCL5-treated groups.  Significance (* p < 0.05, ** p < 0.01) was determined 
using Student’s t test.      
 119
0.00
5.00
10.00
15.00
20.00
25.00
saline rgpCCL5
m
R
N
A
 fo
ld
 in
du
ct
io
n
IFN gamma
TNF alpha
IL-1 beta
IL-12p40
** *
A
*
0.00
50.00
100.00
150.00
200.00
250.00
300.00
saline rgpCCL5
m
R
N
A
 fo
ld
 in
du
ct
io
n
CCL5
CCL2
CXCL8
B
p=0.056
 120
Figure 28:  Effect of anti-CCL5 on cytokine and chemokine mRNA in pleural cells 
obtained from BCG-vaccinated guinea pigs 4 days post-pleurisy induction.  Total RNA 
was isolated, reverse transcribed, and cDNA was analyzed by real-time PCR.  Results 
were expressed as fold induction of mRNA, which was determined by normalizing 
cytokine/chemokine threshold cycle (Ct) values against HPRT values.  This was further 
normalized against mRNA from pleural cells obtained from pleurisy-free (no antigen 
injected) animals.  Panel A:  exhibits data comparing cytokine mRNA levels in IgG 
control treated compared to anti-rgpCCL5 treated groups.  Panel B:  exhibits data 
comparing chemokine mRNA levels in IgG control treated compared to anti-rgpCCL5 
treated groups.  Data represent mean + SEM of 3-4 animals per group.  Significance (* p 
< 0.05) was determined using Student’s t test.      
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Expression of all cytokines tested (Fig. 28A).  Guinea pigs treated with anti-rgpCCL5 
displayed similar expression levels between IFNγ and IL-12p40 (Fig. 28A).  
Approximately 10-fold greater CCL5 mRNA levels were observed compared to all other 
chemokine mRNA levels tested (Fig. 28B).  Comparative studies illustrated reduced 
levels of CCL2 (p < 0.05), with decreasing trends, though not significant, in IFNγ (p < 
0.1) and TNFα (p < 0.1) in animals treated with daily anti-rgpCCL5 compared to isotype 
control.  Levels of CCL5 mRNA were significantly enhanced (p < 0.05) in guinea pig 
population given daily doses of anti-CCL5 compared to rabbit IgG isotype controls.  
Figures 29A and B display the cytokine/chemokine mRNA levels from pleurisy induced 
guinea pigs without daily anesthesia (control) compared to animals with daily anesthesia 
and injections (saline).  Levels of IFNγ were significantly diminished (p < 0.05) in the 
control group compared to the saline group (Fig. 29A).  Anesthesia treatment did not 
affect the other cytokine and chemokine mRNA levels (Fig. 29A and B). 
Severity and cellular composition of granulomas.  Granulomas were isolated 
from BCG-vaccinated guinea pigs 4 days after tuberculous pleurisy was induced.  Figure 
30 illustrates the overall severity of the inflammatory response (Fig. 30A) and cellular 
composition from histological examination (Fig. 30B) using a scoring method depicted 
in table 3.  There were minimal differences between the treatment groups at this stage of 
the inflammatory process.  During this early time period, granulomas were difficult to 
score resulting in variability within each slide.  Though not significant, the anti-CCL5 
treated group displayed the greatest overall severity among the treatment groups.  In Fig. 
30B the overall cellular composition throughout the histological sections were scored.   
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Figure 29:  Effect of daily anesthesia on cytokine and chemokine mRNA in pleural cells 
obtained from BCG-vaccinated guinea pigs 4 days post-induction.  Total RNA was 
isolated, reverse transcribed, and cDNA was analyzed by real-time PCR.  Results were 
expressed as fold induction of mRNA, which was determined by normalizing 
cytokine/chemokine threshold cycle (Ct) values against HPRT values.  This was further 
normalized against mRNA from pleural cells obtained from pleurisy-free (no antigen 
injected) animals.  Panel A:  exhibits data comparing cytokine mRNA levels in daily 
anesthesia (saline) group compared to day 0 anesthesia only (control).  Panel B:  exhibits 
data comparing chemokine mRNA levels in daily anesthesia (saline) group compared to 
day 0 anesthesia only (control).  Data represent mean + SEM of 3-4 animals per group.  
Significance (* p < 0.05) was determined using Student’s t test. 
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Table 3:  Scoring of granulomas 4 days post-induction 
Severity rankinga Characteristics of granuloma/cellular and  bacilli accumulation 
 
0 
 
1 
 
No change/presence  
 
Minimal change/presence 
 
2 
 
Mild change/presence 
 
3 
 
Moderate change/presence 
                    4 Severe change/presence 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     a An arbitrary system was designed to assess the overall inflammatory severity, the concentration of leukocyte populations, 
and bacterial burden within the granulomas.   
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Figure 30:  Characterization of granulomas derived after 4 days post-tuberculous 
pleurisy induction.  Granulomatous tissue was sectioned and stained with H & E.  The 
overall inflammatory severity was scored according to Table 3 and is displayed in panel 
A.  Leukocyte populations were scored within the granulomatous tissue and 
characterized in panel B.  Results represent the mean + SEM of 3-4 animals per 
treatment group.  
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Once again, much variability was exhibited within each single animal.  Overall there 
were no significant differences between cell populations in different treatment groups, 
however, the neutrophils seemed slightly elevated with about 1 score greater in the anti-
CCL5 treated group compared to the other groups.       
Cytokine/chemokine gene expression in granulomas isolated from 
tuberculous pleurisy.  Total RNA was isolated from the whole granulomas, reverse 
transcribed, and analyzed via real-time PCR.  Table 4 compares cytokine/chemokine 
mRNA expression in granulomas obtained from saline, rgpCCL5-treated, IgG (isotype 
controls)-treated, anti-rgpCCL5-treated, or control (only anesthetized on day 0 to induce 
pleurisy) groups.  Minimal differences were observed between treatment groups given 
daily injections due to the large variability in gene expression within granulomas.  
However, a trend was apparent, with the rgpCCL5 treated group exhibiting the lowest 
TNFα and highest IL-12p40 mRNA levels compared to all the treatment groups given 
daily injections and anesthesia.  Pleuritic guinea pigs receiving anti-rgpCCL5 exhibited 
the lowest IFNγ, IL-12p40, and CXCL8 mRNA expression of any treatment group.  
However, CCL2 mRNA expression was the highest in the group given daily doses of 
anti-rgpCCL5.  The effect of daily anesthesia on mRNA in granulomas was 
demonstrated by significantly (p < 0.05) higher levels of IFNγ and IL-12p40 mRNA in 
granulomas obtained from pleurisy-induced guinea pigs not anesthetized daily compared 
to those undergoing daily anesthesia.  IL-1β mRNA levels were also heightened (p < 
0.05) in animals from the control group compared to all other groups, except saline-
treated guinea pigs.  
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Gene Salineg rgpCCL5g IgGg Anti-rgpCCL5g Controlg
IFN gamma 5.68 + 0.70a 6.50 + 2.25a 9.11 + 1.78a 4.57 + 0.48a 31.50 + 13.31b
IL-12p40 5.68 + 0.46c 7.13 + 0.98c 5.62 + 1.08c 4.43 + 1.45c 11.27 + 1.45d
TNF alpha 5.68 + 1.92 1.76 + 0.65 3.15 + 1.09 3.00 + 1.43 6.06 + 2.12
IL-1 beta 4.93 + 2.23e 2.85 + 1.19f 1.98 + 1.31f 2.41 + 0.68f 6.97 + 0.60e
CCL5 28.82 + 8.86 20.31 + 6.67 21.83 + 4.07 19.25 + 6.31 35.99 + 12.22
CCL2 7.45 + 1.73 6.36 + 2.17 6.58 + 1.35 10.31 + 1.73 8.83 + 3.28
CXCL8 104.79 + 40.02 71.37 + 48.43 36.53 + 17.45 29.77 + 9.97 67.96 + 8.68
e is significant (p < 0.05) from f groups
Table 4:  Expression of cytokine and chemokine mRNA levels within 
 granulomas isolated from pleurisy-induced guinea pigs
a is significant (p < 0.05) from b groups
c is significant (p < 0.05) from d groups
g At day 4 of pleurisy induction, granulomas were isolated, homogenized, and total RNA was isolated.  Results were 
expressed as fold induction of mRNA, which was determined by normalizing cytokine/chemokine threshold cycle (Ct) 
values against HPRT values.  This was further normalized against mRNA from pleural cells obtained from pleurisy-free 
(no antigen injected) animals.  Data represent mean + SEM of 3-5 animals per group.  Significance (p < 0.05) between 
all groups was performed using ANOVA.
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 Effect of gpCCL5 on M. tuberculosis within granulomas.  Ziehl-Neelsen 
stains were performed on histological sections of granulomas obtained 4 days post-
pleurisy induction.  Figure 31 depicts M. tuberculosis numbers within the granulomas 
using the scoring method outlined in Table 3.  This method of quantifying bacilli was 
highly variable within each group, resulting in the absence of statistical significance.  
However, it is important to note that the anti-CCL5 treated group demonstrated the 
highest bacterial burden within the granulomas compared to all other groups.  The 
difference between the mean of rgpCCL5 treated and anti-CCL5 treated exceeded 1 
score group.  This comparison exhibits the largest bacillary difference when comparing 
all other groups.  Histological sections from these two treatment groups after acid-fast 
stain are depicted in Fig. 32.  Samples from each treatment group suggest rgpCCL5-
treated animals (Fig. 32A and C) have diminished bacillary loads compared to anti-
rgpCCL5 treated animals (Fig. 32B and D) within granulomas.     
   
DISCUSSION 
Tuberculous pleurisy remains one of the leading extrapulmonary manifestations 
of tuberculosis infections (3, 180).  However, it presents usually as a self-limiting 
disease controlled by the host cell-mediated immune response.  As a result, it serves as a 
potential model to dissect the important molecules involved in a local, protective 
antimycobacterial immune response.  Our results support previous studies demonstrating 
the ability of CCL5 to be chemotactic to T lymphocytes (166, 175) at concentrations of 
125-1250ng/ml (Fig. 22A).  These chemotactic properties were neutralized when  
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Figure 31:  The effect of modifying local CCL5 activity on M. tuberculosis within the 
granuloma.  Histological slides were prepared from granulomas on day 4 post-
tuberculous pleurisy induction from BCG-vaccinated guinea pigs given various daily 
treatments including:  rabbit IgG control, rgpCCL5, anti-rgpCCL5, or saline.  
Histological sections were acid-fast stained and scored according to the description 
depicted in Table 3.  Results display the mean + SEM of 3-4 animals per treatment 
group.  
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Figure 32:  The effect of local modulation of CCL5 on bacillary loads within granulomas 
taken at day 4 post-pleurisy induction.  BCG-vaccinated guinea pigs were induced with 
tuberculous pleurisy, and on day 4 granulomas were obtained and histological sections 
were acid-fast stained using Ziehl-Neelsen staining to determine bacterial burdens within 
granulomas.  Panel A represents a granuloma from rgpCCL5-treated group 
(magnification ×200).  Panel B represents a granuloma from anti-rgpCCL5 treated group 
(magnification ×200).  Panel C and D are enlarged pictures of the localized areas 
depicted by squares in panels A and B respectively.  Arrows were used in panels C and 
D to depict M. tuberculosis bacilli (pink) within granulomas.
A
B
C
D
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RgpCCL5 was incubated with rabbit anti-rgpCCL5 in a dose dependent manner (Fig. 
22B), with complete neutralization of rgpCCL5 (375ng/ml) observed at 100µg/ml of 
anti-rgpCCL5.   
 Characterization of the role of gpCCL5 during tuberculous pleurisy was 
determined by giving daily injections of rgpCCL5 or anti-rgpCCL5 for 4 days.  Previous 
studies showed optimal CCL5 mRNA and protein concentrations were seen at 4 days 
(see Chapter IV) with optimal fluid levels accruing at days 4 and 5 (8).  Pleuritic guinea 
pigs given rgpCCL5 at daily intervals had significantly elevated fluid levels compared to 
saline alone (Fig. 23A).  These results coincided with elevated levels of cells in the 
pleural cavity in animals given rgpCCL5 daily (data not shown).  The chemotactic 
effects of CCL5 on T lymphocytes (166, 175), monocytes/macrophages (27), neutrophils 
(147), and eosinophils (4) suggests a plausible explanation for the enhanced cells 
numbers in the pleural effusions.  In the rgpCCL5 treated group, there was slight 
neutrophilia (p < 0.1) with a significant reduction in T lymphocytes (p < 0.05) (Fig. 24A 
and 25A).  The presence of neutrophilia in the rgpCCL5-treated group supports previous 
studies demonstrating heightened neutrophils during inflammation when CCL5 is being 
over-expressed in vivo (4, 25).  However, those studies also exhibit enhanced levels of T 
lymphocytes and monocyte/macrophages in rodents with CCL5 over-expression.  Those 
results contradict our findings, but the levels of CCL5 in lungs from those studies were 
undetermined or less than 200pg/ml.  Since we injected greater than 10,000-fold higher 
concentrations (6.25µg/side/day) of CCL5 into a localized area, these results are difficult 
to correlate.  One explanation is that the rgpCCL5 concentration used in this study was 
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above the chemotactic concentration.  Future studies will look at the effects of lower 
rgpCCL5 doses on leukocyte populations within the pleural cavity during the 
development of pleurisy in this model.    
The absence of guinea pig reagents to determine if the T lymphocytes are of the 
memory phenotype leaves more unanswered questions regarding these results.  In an 
attempt to address the presence of memory T lymphocytes, spontaneous and antigen-
specific proliferation was measured.  A lack of significant differences between 
rgpCCL5-treated and saline-treated groups in spontaneous proliferation (immediately ex 
vivo) might be due to the high levels of CCL5 already present in the pleural fluid 
(Chapter V, Fig. 6), or to the significantly elevated T lymphocyte population present in 
the saline group compared to the rgpCCL5 group.  However, Fig. 26C exhibits 
significantly higher proliferation in pleural cells obtained from rgpCCL5 treated groups 
compared to saline alone when stimulated with PPD (25µg/ml).  These results suggest 
that there was a heightened population of memory T lymphocytes in the group given 
rgpCCL5 daily, supporting a previous study demonstrating human memory T 
lymphocyte chemotaxis to CCL5 (175).     
 IFNγ mRNA expression levels were 10-fold greater in pleural effusion cells than 
in cells isolated from pleurisy-free BCG-vaccinated guinea pigs.  These findings are in 
agreement with other studies showing heightened IFNγ mRNA levels in guinea pigs and 
humans with tuberculous pleuritis (8, 18).  These enhanced levels are the result of local 
cell-mediated immunity in the pleural space, which was demonstrated by Allen et al. (6).  
Comparative studies between rgpCCL5 and saline treated groups during tuberculous 
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pleuritis demonstrated significantly lower levels of IFNγ mRNA in guinea pigs receiving 
daily doses of rgpCCL5 (Fig. 27A).  Previous studies linking CCL5 with IFNγ 
production by human and murine antigen-specific CD4+ and CD8+ T lymphocytes cell 
lines (11, 110) contrast with the current findings.  However, considering that the saline 
treated group had twice the percentage of T lymphocytes in the pleural effusion cell 
population and twice the IFNγ mRNA expression levels than the group treated with 
rgpCCL5, it would suggest the increase in IFNγ mRNA levels is due to the elevated 
percentage of T lymphocyte and not to enhanced mRNA levels on a per cell basis. 
 TNFα mRNA levels were elevated in all pleuritic BCG-vaccinated guinea pigs 
(Fig. 27A).  These results agree with other studies showing heightened TNFα mRNA 
levels in pleural cells obtained from humans and guinea pigs with pleuritis (8, 18) and 
elevated TNFα protein levels in human tuberculous pleurisy (137).  Comparative studies 
between rgpCCL5 and saline treated guinea pigs revealed no significant difference.  The 
proinflammatory cytokine, IL-1β, mRNA levels were significantly enhanced in guinea 
pigs given daily doses of rgpCCL5 (Fig. 27A) though the fold induction levels in both 
groups were below 5.  These findings agree with data demonstrating the ability of 
rgpCCL5 to enhance IL-1β mRNA in macrophages (113, 184).  IL-1β protein in pleural 
effusions from humans with tuberculous pleuritis exhibited minimal levels usually below 
200pg/ml (183). 
 Analysis of the Th1 cytokine subunit, IL-12p40 mRNA, revealed significantly 
higher levels in rgpCCL5 treated animals compared to saline alone (Fig. 27A).  These 
are novel findings suggesting a role of rgpCCL5 in favoring a Th1 response, which has 
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been demonstrated previously in mice (54).  The differences in cell populations do not 
seem to correlate proportionally with the 5-10 fold increase in IL-12p40 from the 
rgpCCL5-treated group, suggesting that rgpCCL5 enhances the expression of IL-12p40 
mRNA in cells stimulated with daily injections of rgpCCL5 compared to saline alone.  
We have demonstrated enhanced IL-12p40 mRNA levels in resident and alveolar 
macrophages stimulated with ~1µg/ml rgpCCL5 (data not shown).   
 MRNA levels of CXCL8 and CCL5 appear to be heightened at day 4 after 
pleurisy induction in BCG-vaccinated guinea pigs (Fig. 27B), with CCL5 mRNA being 
expressed at levels greater than 10-fold higher compared to CXCL8 and CCL2.  These 
results provide support for a previous study looking at pleurisy in mice.  Fine et al. 
demonstrated a gradual reduction of numerous chemokines, including CCL2, from 6 h to 
72 h except for CCL5, which displayed a gradual increase in mRNA expression through 
72 h post-induction (60).  Comparison between saline and rgpCCL5-treated animals 
illustrated lower trends, though not significant, of CXCL8 (p < 0.1) mRNA in guinea 
pigs given daily injections of rgpCCL5 (Fig. 27B).  These data are supported by 
previous results in Chapter II regarding the ability of rgpCCL5 to upregulate CXCL8 
mRNA in macrophages.  It must also be noted that there was a slight increase, though 
not significant, in neutrophils in rgpCCL5 treated animals (Fig. 25A), suggesting this 
heightened expression could be due to the differences in cell populations in the pleural 
cavity.  However, Pace et al. observed production of CXCL8 in patients with 
tuberculous pleurisy and correlated its presence with an enhanced T lymphocyte (not 
neutrophil) accumulation (146).  These results are difficult to interpret due to an absence 
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of CXCL8 kinetics throughout the development of pleurisy.  The reduced expression of 
CCL5 mRNA (p = 0.056) in the rgpCCL5-treated group might be due to the diminished 
presence of T lymphocytes in the pleural space or a downregulation by the host to limit 
the production of CCL5.  Studies looking at protein levels of CXCL8 and CCL5 need to 
be performed before further conclusions can be made.   
 Due to the variation in the methodology for acquiring pleural cells, the anti-
CCL5 and rabbit IgG control groups cannot be compared with data from the rgpCCL5- 
and saline-treated groups.  There were significant differences between the anti-rgpCCL5 
and IgG isotype control groups in pleural fluid and severity (Fig. 23B).  The anti-
rgpCCL5 group produced significantly more pleural fluid and had enhanced severity 
compared to the IgG isotype control.  In conjunction with the data in Fig. 24 and 25 on 
the cellular composition in the pleural fluid and wash, these data suggest that anti-
rgpCCL5 treatment blocked recruitment of MHC class II expressing cells (Fig. 24B), 
including macrophages (Fig. 25B), and enhanced the accumulation of eosinophils (p < 
0.05) (Fig. 25B) compared to the IgG isotype control.  The reduction in macrophages 
and other MHC class II expressing cells in the anti-CCL5 treated group supports the role 
of CCL5 in attracting these cells to the site of inflammation (27).  Together, the presence 
of eosinophilia and reduced macrophages suggests diminished polarization towards a 
Th1 response. 
 Previous studies have demonstrated that CCL5 can induce spontaneous, as well 
as antigen-specific, proliferation in T lymphocytes (11, 14, 110, 121, 193).  As a result, 
we looked at proliferation of lymphocytes directly coming out of the pleural cavity 
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(immediately ex vivo).  A significant reduction of spontaneous proliferation was 
apparent in cells obtained from the anti-rgpCCL5 treated group (Fig. 26B), suggesting 
that CCL5 was involved in the proliferative responses occurring within the pleural cavity 
at day 4 following the induction of tuberculous pleurisy.  In support of these findings, 
Makino et al., reported diminished polyclonal and antigen-specific T lymphocytes 
proliferation in CCL5 -/- mice compared to wild type mice (121).  Lillard et al. also 
observed enhanced ova-specific T lymphocyte proliferation in mice receiving rCCL5 in 
vivo (110).  PPD-specific proliferation was not performed in these experiments, but will 
be analyzed in future experiments to support this theory of CCL5’s involvement in 
proliferative activity.     
 Previous studies have demonstrated the ability of CCL5 to affect 
cytokine/chemokine expression in different types of leukocytes (11, 35, 110, 113, 184).  
In the present study, we showed a trend, though not significant, toward reduced IFNγ 
mRNA expression from pleural cells obtained from the anti-CCL5 treated group (Fig. 
28A).  Unlike the large variation in T lymphocyte populations between rgpCCL5 and 
saline treated groups, the anti-CCL5 and IgG control groups had similar T lymphocyte 
populations.  This findings confirm previous studies exhibiting the presence of CCL5 
with heightened IFNγ expression and production (35, 110, 121).  Chensue et al. reported 
enhanced IFNγ production in type1 granulomas in mice treated with rhCCL5.  Another 
study performed by Makino et al. exhibited diminished IFNγ production by antigen-
specific T lymphocytes from CCL5 -/- mice.   
 138
 The proinflammatory cytokine TNFα exhibited slightly diminished mRNA 
levels, though not significant, in animals treated with anti-CCL5 (Fig. 28A).  These 
results may be due to a reduction in macrophages, and an increase in neutrophils and 
eosinophils (Fig. 25B).  In Chapter II, it was demonstrated that rgpCCL5 stimulated 
alveolar and peritoneal macrophages to enhance TNFα mRNA and protein levels, 
further supporting these findings. 
 Chemokine levels were also affected by neutralization of CCL5.  CCL5 mRNA 
was significantly enhanced (p < 0.05) in the group given anti-rgpCCL5 (Fig. 28B) 
suggesting that the animals were trying to compensate for the low levels of CCL5.  
CCL2 was significantly (p < 0.05) diminished in animals treated with anti-CCL5, 
however, the expression levels were similar to those seen in pleural cells obtained from 
pleurisy-free (not injected with antigen) BCG-vaccinated guinea pigs.   
 The role of CCL5 in granuloma formation is not well understood.  We 
demonstrated similar overall inflammatory severity in the granulomas between the 
treatment groups, with the anti-rgpCCL5-treated animals displaying slightly higher 
severity compared to the other groups, though not statistically significant (Fig. 30A).  
This increase in severity among the anti-CCL5 treated guinea pigs correlates with 
slightly enhanced neutrophilia (Fig. 28B), as compared to other groups.  These 
granulomas were in the early phase of development and, as a result, were difficult to 
score and had a range of variability resulting in a lack of significance.  Previously, 
Chensue infused rhCCL5 (20µg/day) into mice two days before challenging the mice 
with PPD-coated beads (35).  These animals displayed no differences in cellular 
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composition and granuloma size on day 3.  Likewise, when they infused anti-mCCL5 
into mice injected with PPD-coated beads, they observed no effect on cellular 
composition.  This correlated with our results exhibiting limited differences in leukocyte 
populations within the granulomas containing altered CCL5 protein levels.  However, 
leukocyte numbers were not quantified and multiple days were not analyzed, thus 
limiting our abilities to make further conclusions.      
 The levels of cytokine and chemokine mRNA inside the granulomas were quite 
variable, with no statistical significance displayed between the four treated groups.  
However, the rgpCCL5-treated animals groups had the highest levels of IL-12p40 
mRNA over all other groups with daily anesthesia.  Animals treated with anti-rgpCCL5 
daily displayed the lowest levels of IFNγ, IL-12p40, and CXCL8 mRNA compared to 
other groups receiving daily injections and anesthesia.  Although not significant due to 
the small number of animals tested and large variability, the trend seems to confirm 
studies correlating CCL5’s presence with enhanced levels of these inflammatory genes 
(54, 121, 184).  It is interesting to note that all the leukocyte populations were similar 
within the granulomas except neutrophils, which predominated in the anti-CCL5 treated 
group.  However, this group also had the lowest CXCL8 mRNA expression, suggesting 
CCL5 may be linked to CXCL8 expression, which is supported by the findings in 
Chapter II demonstrating rgpCCL5’s ability to elevate CXCL8 expression in 
macrophages. 
 The lower levels of cytokine and chemokine mRNA in the anti-rgpCCL5 treated 
group related to enhanced bacillary loads, though not significant, within granulomas 
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(Fig. 31 and 32) compared to all other groups receiving daily anesthesia.  These results 
are supported by a previous study performed by Saukkonen et al. that demonstrated 
enhanced M. tuberculosis viability within human alveolar macrophages co-cultured with 
anti-hCCL5 (174).  The largest variation in bacterial burdens between groups was 
observed in the rgpCCL5 and anti-rgpCCL5 treated groups (Fig. 31 and 32), suggesting 
that CCL5 has a role in M. tuberculosis viability.  Future studies will be focused on 
deciphering these protective mechanisms elicited by gpCCL5, and its role in tuberculous 
pleurisy as the granulomas mature.  
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CHAPTER VII 
CONCLUSIONS 
 
One third of the world’s population remains infected with M. tuberculosis with 
an annual mortality reaching ~ 2 million deaths.  In this dissertation, our goal was to 
understand the role of gpCCL5 during a tuberculosis infection in the guinea pig model 
and the effect that BCG-vaccination has on its production.  Our first aim of these studies 
was to produce and characterize rgpCCL5 and anti-rgpCCL5.  We subcloned the mature 
guinea pig cDNA into pET30Xa/LIC vector, transformed the vector into an E. coli 
strain, and expressed it using IPTG.  The protein was refolded, purified using reverse 
phase HPLC, cleaved to obtain mature rgpCCL5, and re-purified over a C4 column 
using reverse phase HPLC.  The recombinant protein was chemotactic for both T 
lymphocytes and peritoneal exudate cells with an optimal concentration ~ 1350ng/ml.  
We injected rabbits with rgpCCL5 and obtained rabbit polyclonal anti-rgpCCL5 serum, 
which bound rgpCCL5 on a Western blot.  This antibody neutralized the chemotactic 
effect for T lymphocytes.   
 We demonstrated the ability of rgpCCL5 (~ 1µg/ml) to significantly stimulate 
TNFα, IL-1β, CCL2, and CXCL8 mRNA and TNFα protein in peritoneal and alveolar 
macrophages.  These results suggest that rgpCCL5 is not only attracting leukocytes to 
the site of inflammation, but enhancing numerous inflammatory cytokines and 
chemokines in preparation for an antigenic encounter.  We demonstrated that the pre-
stimulation of cells with rgpCCL5 resulted in diminished levels of chemokines and 
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cytokines when cells were exposed subsequently to LPS.  Future studies will elucidate 
the affect of rgpCCL5 pre-treatment on macrophages stimulated with mycobacterial 
antigens.   
 Previous studies have demonstrated the mitogenic and antigen-specific 
proliferative activities of CCL5 at various concentrations (14, 110, 193).  In preliminary 
studies reported in Chapter III, we saw limited effects of rgpCCL5 on splenocyte 
proliferation to both mitogenic and antigenic (PPD) stimuli.  However, in Chapter VI 
pleural effusion cells exhibited a significant reduction in spontaneous proliferation ex 
vivo from pleuritic guinea pigs given anti-rgpCCL5 compared to IgG controls, and the 
rgpCCL5 treated group demonstrated elevated antigen (PPD)-specific proliferation 
compared to saline alone.  These data suggest gpCCL5 is involved in T lymphocyte 
proliferation and further in vitro studies need to be performed to examine isolated T 
lymphocytes exposed to varying concentrations of rgpCCL5 alone or in combination 
with PPD.  
 Saukkonen et al. reported enhanced M. tuberculosis viability in human alveolar 
macrophages co-cultured with anti-CCL5 (174).  We observed minimal effects of 
rgpCCL5 on M. tuberculosis viability within peritoneal and alveolar macrophages.  
Preliminary studies did show that macrophages isolated from BCG-vaccinated guinea 
pigs controlled M. tuberculosis better than macrophages from naive animals.  Jackett et 
al. demonstrated enhanced H2O2 from macrophages isolated from BCG-vaccinated 
compared to naive guinea pigs 3 days after intravenous infection with M. tuberculosis 
(H37Ra) (84).  These findings led us to examine a possible influence of gpCCL5 on 
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H2O2 production.  Our preliminary studies failed to demonstrate a correlation with H2O2 
production and gpCCL5 stimulation in M. tuberculosis-infected macrophages.  In 
summary, this ability of CCL5 to alter intracellular M. tuberculosis viability still remains 
to be elucidated in the guinea pig model. 
BCG-vaccination induces effective protection against M. tuberculosis in the 
guinea pig, therefore, we characterized variations in host immunity between naive and 
BCG-vaccinated guinea pigs.  Levels of IL-12p40 mRNA were elevated significantly in 
M. tuberculosis-infected alveolar macrophages from BCG-vaccinated compared to naive 
guinea pigs.  We also demonstrated increased IL-12p40 mRNA levels at early culture 
intervals in alveolar macrophages infected with virulent M. tuberculosis (H37Rv) 
compared to an attenuated strain (H37Ra).  This pattern was reversed later in the 
infection (post-18 h).  These results further support previous studies demonstrating the 
role of IL-12/IL-23 in providing protection against M. tuberculosis (2, 39, 78).       
 For the first time, we quantified gpCCL5 protein levels using an ELISA 
developed from rabbit polyclonal anti-rgpCCL5 serum.  Significantly enhanced levels of 
CCL5 mRNA and protein were observed in alveolar and peritoneal macrophages, as well 
as splenocytes, infected with virulent M. tuberculosis (H37Rv) in vitro.  These results 
supported a previous study performed in our laboratory exhibiting increased CCL5 
mRNA in peritoneal exudate cells obtained from BCG-vaccinated guinea pigs compared 
to naive animals and infected with M. tuberculosis (85).  It also supports previous 
studies demonstrating heightened CCL5 production in human alveolar macrophages 
infected with M. tuberculosis (167).  We looked at the production of gpCCL5 in vivo 
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during tuberculous pleurisy and demonstrated significantly elevated levels of gpCCL5 
mRNA in pleural exudate cells and protein in the pleural fluid as the infection 
progressed reaching peak levels on day 4.           
 These results prompted us to look further into the effect of modifying local 
activity of gpCCL5 during tuberculous pleurisy.  We induced tuberculous pleurisy in 
BCG-vaccinated guinea pigs and administered daily bilateral injections of either 
rgpCCL5, saline, anti-rgpCCL5, or IgG isotype control.  On day 4 post-induction, the 
animals were exsanguinated, and pleural fluid/cells and granulomas were collected.  
Exogenous addition of large concentrations of rgpCCL5 (6.7µg/side/day) compared to 
saline during tuberculous pleurisy resulted in elevated leukocyte migration and pleural 
fluid accumulation.  Cellular accumulation exhibited slight neutrophilia, correlating with 
enhanced CXCL8 mRNA expression in rgpCCL5-treated guinea pigs, and a diminished 
percentage of T lymphocytes, which was proportional to the reduced IFNγ mRNA levels 
in the pleural exudate cells.  Although saline-treated animals had significantly more T 
lymphocytes than rgpCCL5-treated animals, when pleural exudate cells were stimulated 
with PPD, those cells from the rgpCCL5-treated group exhibited significantly elevated 
proliferation.  This group also had elevated levels of IL-12p40 and IL-1β mRNA 
compared to saline alone.  Neutralizing local activity of gpCCL5 with anti-rgpCCL5 
treatment resulted in significantly elevated severity of inflammation, with suppressed 
macrophage, but elevated eosinophil, accumulation.  This suggests a polarization 
towards a Th2 , rather than a Th1, response.  In support of this conclusion, IFNγ and 
TNFα were diminished in anti-rgpCCL5-treated guinea pigs compared to IgG controls.  
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Diminished spontaneous proliferation was also observed in the pleural effusion cells 
from animals receiving anti-rgpCCL5.  A tendency toward increased bacillary loads in 
the granulomas from anti-rgpCCL5 supports the conclusion that neutralizing CCL5 
resulted in an inefficient or delayed cell-mediated immune response.  
Cytokine/chemokine mRNA expression levels were not significantly different among 
treatment groups due to the small number of animals and large variability between them, 
however, anti-rgpCCL5 treated animals had the lowest levels of mRNA for IL-12p40 
and IFNγ, both of which are associated with a Th1 response.   
These studies suggest an important role of CCL5 in leukocyte activation and 
protection against M. tuberculosis infections.  From these data and previous data, Figure 
33 demonstrates numerous pathways throughout a M. tuberculosis infection in which 
CCL5 may be involved.  Further studies assessing the production of CCL5 in vivo 
following virulent pulmonary infection are needed, as are studies of the requirement for 
CCL5 in granuloma architecture.  If these studies provide further evidence supporting an 
essential protective role of CCL5 during a M. tuberculosis infection, it would be 
beneficial to design new tuberculosis vaccines which stimulate elevated CCL5 
production when the host was confronted with the bacillus.  Another possible mode of 
protection might be to deliver CCL5 in conjunction with a tuberculosis vaccine as an 
adjuvant.  Previously studies have displayed synergistic protection when expressing 
CCL5 with HIV DNA vaccines (211).       
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Figure 33:  Summary:  The putative role(s) of CCL5 during M. tuberculosis infection.  
From these data and previous studies analyzing the role of CCL5 in the immune 
response elicited against tuberculosis, we suggest 7 areas of CCL5 involvement during 
infection.  Stage 1:  First, CCL5 is chemotactic to T lymphocytes, especially of the 
memory phenotype, and monocyte/macrophages into inflammatory foci.  Stage 2:  Next, 
CCL5 stimulates macrophage TNFα production, which activates macrophages in a 
paracrine and autocrine fashion.  Stage 3:  Then, CCL5 induces release of chemokines 
and Th1 cytokines from macrophages, which results in T lymphocyte migration and 
differentiation of Th0 cells into Th1 lymphocytes.  Stage 4:  Next, CCL5 enhances IL-2 
production, resulting in lymphocyte proliferation and Stage 5:  the release of 
macrophages activating cytokines, IFNγ and TNFα.  Stage 6:  This activation of 
macrophages with IFNγ and TNFα may result in elevated production of ROIs and RNIs, 
which have displayed anti-mycobacterial properties.  Stage7:  Finally, the production of 
IFNγ and TNFα aids in macrophage fusion resulting in epithelioid and giant cell 
formations at the foci of the granuloma.  These cells types display an enhanced anti-
mycobacterial activity, resulting in diminished bacterial viability. 
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